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Approximately a third of patients with schizophrenia do not respond to anti-
psychotic treatment targeting the dopamine system, suggesting that a separable
neural dysfunction may drive psychosis in these patients. This thesis aims to
probe the mechanisms underlying treatment response by investigating two cog-
nitive processes which have been implicated in schizophrenia – cognitive control
and reinforcement learning – as well as brain myelination. The key hypotheses
are that 1) treatment resistant schizophrenia emerges due to a failure to exert
cognitive control, characterised by prefrontal hypoactivation and functional dys-
connectivity, 2) treatment responsive schizophrenia is selectively associated with
a subcortical dopaminergic dysfunction, evident in an abnormal neural signature
of reward prediction error (RPE) during reinforcement learning, and 3) treatment
resistant schizophrenia is characterised by exacerbated structural dysconnectiv-
ity as indexed by myelin content. To dissect these mechanisms, performance and
neural activation during a cognitive control task and a reinforcement learning task,
as well as myelin water fraction (MWF) were compared between 22 treatment re-
sistant patients, 21 treatment responsive patients, and 24 healthy controls. Treat-
ment resistant and responsive patients showed similarly impaired performance on
both tasks compared to controls. During the cognitive control task, resistant
patients showed an inverse correlation between frontal activation and psychotic
symptoms as well as reduced functional fronto-thalamic connectivity compared
to controls. During the reinforcement learning task, responsive patients showed
reduced cortical and subcortical RPE related activation compared to controls and
treatment resistant patients. MWF was reduced in patients compared to controls
in several white matter regions but did not differ between the two patient groups.
The findings support distinct neural mechanisms underlying treatment resistant
and responsive schizophrenia despite similar behaviour. Functional dysconnectiv-
ity within the cognitive control network and a deterioration of frontal activation
as a function of symptom severity may perpetuate psychosis despite dopaminer-
gic treatment in treatment resistant schizophrenia, although this is not reflected
in an exacerbated myelin dysfunction. The results highlight the importance of
stratifying patient samples by treatment response status in future research.
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Schizophrenia is a severe mental disorder which affects approximately 1% of the
population worldwide (Jablensky, 2000). It is characterised by positive (psychotic)
symptoms, negative symptoms, as well as cognitive impairments. Symptoms of
psychosis include delusions, hallucinations, and thought disorder, resulting in an
often distressing distortion of reality. Negative symptoms consist of an absence
of normal functioning due to factors such as flattened affect, anhedonia, social
withdrawal, and diminished expression, constituting a major cause of disability
in schizophrenia. The introduction of antipsychotic medications in the 1950s re-
volutionised the treatment of this devastating illness and drastically improved the
average prognosis for affected individuals. However, a large proportion of pa-
tients – variably estimated to be as large as 40% – do not respond adequately
to antipsychotic medication (Lindenmayer, 2000; Mortimer, Singh, Shepherd &
Puthiryackal, 2010). These patients continue to experience symptoms of schizo-
phrenia and their debilitating effects on every-day life despite optimal treatment.
This form of “treatment resistant” schizophrenia (TRS) continues to be one of the
most significant areas of unmet need in psychiatry, as to date our understanding
of the mechanisms underlying antipsychotic treatment resistance remains incom-
plete.
All currently licensed antipsychotics exert their therapeutic effect via blockade of
dopamine D2 receptors (Kapur & Seeman, 2001; Seeman & Lee, 1975; Seeman,
Lee, Chau-Wong & Wong, 1976), leading to the prevailing theory of subcortical
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hyperdopaminergia in schizophrenia (Kapur, Mizrahi & Li, 2005; Howes & Kapur,
2009). Research has suggested that TRS may not fit into the classic dopamine
model of schizophrenia (Coppens et al., 1991; Wolkin et al., 1989; Demjaha,
Murray, McGuire, Kapur & Howes, 2012; Demjaha et al., 2014; Mouchlianitis
et al., 2015) and may constitute a neurobiologically discrete subtype of the ill-
ness. However there is a distinct lack of research explicitly contrasting TRS with
treatment responsive schizophrenia which could lead to a more effective tailoring
of treatment (Mouchlianitis, McCutcheon & Howes, 2016; Nakajima et al., 2015).
Although there has been an increase in in-vivo structural neuroimaging studies in
recent years, the underlying function of the brain in the context of cognition and
decision making has not been thoroughly explored.
Dysfunctional cognitive processing has long been regarded as a core feature of
schizophrenia (Keefe & Harvey, 2012) and is likely to play an important role
in symptom formation and maintenance (Freeman, Garety, Kuipers, Fowler &
Bebbington, 2002; Garety, Kuipers, Fowler, Freeman & Bebbington, 2001). In
this regard schizophrenia is frequently described in terms of a dysconnection syn-
drome, with symptoms of psychosis emerging as a result of a dysfunctional in-
tegration of different cognitive functions subserved by distributed networks in
the brain (Cannon, 2015; Friston, Brown, Siemerkus & Stephan, 2016; Friston
& Frith, 1995; Stephan, Friston & Frith, 2009). In particular, it has been sug-
gested that impairments in distinct regions of cortico-subcortical networks may
be involved in distinguishable aspects of symptom formation in psychosis. For
example, striatal hyperdopaminergia is thought to cause errors in attributing sa-
lience to reward-predicting stimuli, while dysfunctions of the prefrontal cortex
associated with hypodopaminergia may be involved in delusion formation (Heinz
& Schlagenhauf, 2010). As a result, treatment may target abnormalities in one,
but not another, node of a relevant network. Thus, while antipsychotics attenu-
ate striatal hyperdopaminergia, symptoms may persist despite treatment in the
absence of a normative response from prefrontal cortex.
Intact integration of prefrontally modulated control processes with dopamine
driven reward signals is particularly important during reinforcement learning,
which is known to be impaired in schizophrenia (Gold, Waltz, Prentice, Morris &
Heerey, 2008; Deserno, Schlagenhauf & Heinz, 2016). In this thesis, I will explore
the hypothesis that TRS is characterised by an exacerbated dysfunction of pre-
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frontal cognitive control, particularly in the context of feedback learning. Within
this framework, I will first utilise functional magnetic resonance imaging (fMRI)
in order to compare both the behaviour and underlying neural mechanisms of
treatment resistant and treatment responsive patients with schizophrenia, as well
as healthy control subjects, on a standard measure of cognitive control, the Stroop
task (Stroop, 1935). Following on from this, cognitive control in the context of
feedback learning will be assessed in an fMRI study using a reinforcement learn-
ing task which is known to elicit a cognitive bias (Averbeck & Duchaine, 2009).
In order to perform well on this task, cognitive control has to be exerted so as
to overcome the bias and learn adequately from ongoing feedback. Finally, since
abnormal cognitive integration is likely to be modulated by underlying structural
dysconnectivity, I will assess myelin content in the brain using a novel imaging
technique (mcDESPOT; Deoni, Rutt, Arun, Pierpaoli & Jones, 2008) in order to
determine whether more severe white matter changes in TRS can account for the
lack of response to antipsychotic treatment. The following introductory sections
will provide an overview of antipsychotic treatment and treatment resistance, as
well as an outline of the relevant existing literature on cognitive control, reinforce-
ment learning, and white matter changes in schizophrenia.
1.2 Treatment resistant schizophrenia (TRS)
1.2.1 Pharmacological treatment of schizophrenia
The serendipitous nature of the discovery of antipsychotic medication rarely goes
unmentioned in historical accounts of treatment for schizophrenia (e.g., Kapur &
Mamo, 2003, Carpenter & Davis, 2012). The observation in the 1950s that chlor-
promazine exerts a therapeutic effect on symptoms of psychosis was not borne out
of scientific experimentation following a mechanistic understanding of psychotic
illnesses. Rather, the compound, which had been developed as an antihistamine
for use in general anaesthesia (Charpentier, Gailliot, Jacob, Gaudechon & Buis-
son, 1952), was trialled in psychiatric populations after its “neuroleptic” effects on
the central nervous system were discovered (Delay, Deniker & Harl, 1952; Laborit,
Huguenard & Alluaume, 1952). In the decades that followed, a neuroscientific
understanding of psychosis was built predominantly in the course of studying
16
how chlorpromazine and similar pharmacological agents exert their effects on the
brain. The recognition throughout the 1960s and 1970s that dopamine receptor
antagonism was one of the main mechanisms of action of these drugs (Carlsson
& Lindqvist, 1963), and particularly the findings that the extent of D2 receptor
affinity was closely coupled with their antipsychotic effect, have shaped the pre-
vailing understanding of psychosis as a state of subcortical hyperdopaminergia to
this day (Seeman & Lee, 1975; Seeman et al., 1976; Creese, Burt & Snyder, 1976;
Kapur & Seeman, 2001; Howes & Kapur, 2009).
Antipsychotics are clustered into typical (chlorpromazine being the earliest of this
first generation) and atypical (or second generation) antipsychotics, although the
defining criteria of atypicality are not clearly delineated. Clozapine, the prototype
of atypical antipsychotics, was hailed as showing greater antipsychotic efficacy as
compared with typical antipsychotics chlorpromazine and haloperidol, as well as
a reduced tendency to evoke extrapyramidal side effects (EPS) (Kane, Honigfeld,
Singer & Meltzer, 1988). Thus, atypical antipsychotics are generally classed as
such if they show a therapeutic effect in the absence of significant EPS (Kinon
& Lieberman, 1996). However all antipsychotic medications have in common, to
varying extents, an antagonistic action at the dopamine D2 receptor site (Creese
et al., 1976). D2 receptors are mostly expressed subcortically in the striatum,
thus leading to the dominant aetiological theory of increased striatal dopamine in
schizophrenia (Carlsson, 1988; Kapur, 2003; Abi-Dargham, 2004). Recent devel-
opments in the field of neuroimaging have allowed for explicit tests of this theory
in vivo, overwhelmingly converging on the finding of increased striatal dopamin-
ergic neurotransmission in schizophrenia (Hietala et al., 1995; Abi-Dargham et
al., 1998; Lindström et al., 1999; Abi-Dargham et al., 2000; Meyer-Lindenberg
et al., 2002). However, despite these breakthrough developments in the treatment
and neurobiological understanding of schizophrenia, a number of contradictions
and obscurities remain. One is that atypical antipsychotics can have somewhat
lower affinity to D2 receptors, yet have showed at least equivalent efficacy to
typical antipsychotics. Reduced blockade of D2 receptors is likely the cause for
an improvement in EPS, which could in turn ameliorate concomitant negative
and cognitive symptoms. However, it is more difficult to explain the at least
equal, if not increased, efficacy in treating positive symptoms. The second, and
related issue, is that only few antipsychotic drugs are selective dopamine D2 ant-
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agonists, and most exert effects on a wide range of receptors, including other
dopaminergic (D1, D3, D4), serotonergic, muscarinic cholinergic, and histamine
receptors. The extent to which action at other receptor sites increases the thera-
peutic effects of antipsychotics remains elusive, although atypical antipsychotics
have been suggested to improve symptoms as a function of their 5HT2/D2 af-
finity ratio (Meltzer, Matsubara & Lee, 1989). A further, crucial point is that
schizophrenia is characterised not only by psychotic symptoms, but also debilitat-
ing negative and cognitive symptoms, impacting on individuals’ affective, social,
volitional, and motivational lives. Currently licensed antipsychotic medications
have very limited efficacy in treating these symptoms. Lastly, antipsychotic med-
ication proves ineffective in treating symptoms in a large remaining proportion
of patients with schizophrenia despite adequate dopamine D2 receptor binding
(Wolkin et al., 1989; Coppens et al., 1991).
Taken together, a dopamine dysfunction is unlikely to be the primary or sole
neurobiological aetiological factor in the development of schizophrenia. Research
into the development of new antipsychotic drugs has focused on other neurobiolo-
gical targets including the glutamate, gamma amino butyric acid (GABA), sero-
tonin, and acetylcholine systems, as well as inflammation and oxidative stress (Ke-
shavan, Lawler, Nasrallah & Tandon, 2017). However to date, these approaches
have not been successful in clinical trials and dopamine antagonism remains the
main mechanism of action of all currently approved antipsychotic drugs.
1.2.2 Definitions and course of TRS
Approximately 30-40% of patients with a diagnosis of schizophrenia are considered
to be treatment resistant (Lindenmayer, 2000; Mortimer et al., 2010). Concep-
tually, TRS is characterised by a lack of symptomatic response to antipsychotic
medication at adequate dose and duration. In practice, however, the precise
definition of “adequacy” in terms of medication dose and duration has varied
throughout the literature, as has the extent of symptomatic change required to
constitute response (Suzuki et al., 2012). A widely adopted approach to opera-
tionalising TRS with respect to these issues was first offered by Kane et al. (1988),
who proposed the following criteria for treatment resistance:
• at least three previous periods of treatment with antipsychotics at dosages
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of ≥1000 mg per day of chlorpromazine (or equivalent) for a period of at
least six weeks without symptomatic relief
• no period of good functioning in the preceding five years.
• score of ≥45 on the Brief Psychiatric Rating Scale (BPRS)
• severity score ≥4 on two or more BPRS psychotic symptom items
However, these criteria have been modified by several groups in recent years to re-
flect a more inclusive definition of TRS. Since it has become increasingly clear that
patients who failed to respond to two antipsychotic treatment trials are highly un-
likely to respond to a third (Kinon, Kane, Perovish, Ismi & Koreen, 1992), there
is a general consensus that two failed treatment periods are just as predictive as
three to establish treatment resistance (Conley & Kelly, 2001). Similarly, recent
operationalisations of TRS require previous treatments to have been administered
at 400 mg (Conley & Kelly, 2001) or 600 mg (Suzuki et al., 2012) chlorpromazine
equivalent per day. The Maudsley Prescribing Guidelines in Psychiatry (D. M.
Taylor, Paton & Kapur, 2015) in fact recommends a consideration of patients as
treatment resistant if they have failed to respond to at least two previous me-
diations at at least minimum effective dosage. Criteria for psychopathological
severity differ depending on whether studies are cross-sectional, therefore requir-
ing an absolute threshold of symptom severity, or prospective, allowing for a
direct assessment of symptom reduction post-treatment. In the latter case, good
response to treatment is typically defined as a >20% symptom reduction on the
BPRS or Positive and Negative Symptom Scale (PANSS; Kay, Flszbein & Opfer,
1987) compared to baseline (Kane et al., 1988; Elkis, 2007; Suzuki et al., 2012).
Cross-sectional studies typically retain Kane et al.’s (1988) criterion of a score
of 4 (moderate severity) or more on at least two positive symptom items of the
BPRS or PANSS. In 2016, the Treatment Response and Resistance in Psychosis
(TRRIP) working group was formed to review and revise consensus guidelines
for defining treatment resistant schizophrenia in clinical trials. The minimum
requirement for TRS agreed upon by this group includes symptoms of at least
moderate severity for 12 weeks or more; two or more past adequate treatment
episodes with different antipsychotic drugs for 6 weeks or more at an equivalent
dosage of 600mg chlorpromazine a day; and medication adherence of at least 80%
of the prescribed doses (Howes et al., 2016).
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In their seminal study, Kane et al. (1988) established the superior efficacy of cloza-
pine in treating patients who meet criteria for TRS. Around 50% of treatment res-
istant patients are thought to respond to clozapine (Chakos, Lieberman, Hoffman,
Bradford & Sheitman, 2001). Clozapine remains, to this day, the mainstay treat-
ment for TRS; however, due to the potentially severe adverse effects associated
with the drug (J. Nielsen, Correll, Manu & Kane, 2013), notably the increased
risk for agranulocytosis, it remains underprescribed. Once prescribed, it requires
ongoing haematological and physiological monitoring (Beck et al., 2014), but side
effects can generally be well managed with the relevant expertise (D. D. Miller,
2000). Despite this, clozapine prescribing is delayed in the UK, with an average of
4 to 5 years delay before clozapine initiation (D. M. Taylor, Young & Paton, 2003;
Howes et al., 2012). In 2001, patients in southeast London experienced an average
of 9.2 medication prescription trials prior to clozapine (D. M. Taylor et al., 2003),
in contrast to the recommended two. This period of inadequately treated TRS is
likely to increase the burden both on the affected individuals and the health care
system (Aitchison & Kerwin, 1997; Essock, Frisman, Covell & Hargreaves, 2000;
Hayhurst, Brown & Lewis, 2002).
TRS is associated with a large number of adverse consequences. Treatment res-
istant patients require more frequent and longer hospitalisations compared to the
average schizophrenia population (Lindenmayer, 2000). As a result, TRS takes
up a disproportionate volume of the total cost for treating schizophrenia, with a
recent estimation lying at approximately 60-70% of total costs (Kennedy, Altar,
Taylor, Degtiar & Hornberger, 2014). The burden associated with TRS is further
evidenced in a significant decrement in quality of life, as well as an increase in sui-
cide risk, violence, and comorbidity rates (Kennedy et al., 2014; Conley & Kelly,
2001). There is consistent evidence that persistent symptoms despite treatment
result in significant cognitive and functional decline (Strassnig & Harvey, 2014;
Harvey & Rosenthal, 2016). Several recent studies have shown that treatment
refractory patients exhibit greater cognitive impairment as well as negative symp-
toms compared to treatment responsive patients (de Bartolomeis et al., 2013;
Frydecka, Beszlej, Goscimski, Kiejna & Misiak, 2016), and are more impaired
in their everyday functioning (Iasevoli et al., 2016). Importantly, TRS becomes
more difficult to treat as the illness progresses, with time to remission increasing
with each consecutive relapse (Lindenmayer, 2000). The importance of identifying
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TRS early on in the illness was highlighted by two recent studies showing that
70-80% of TRS patients are in fact treatment resistant from illness onset, but still
experience long delays to clozapine initiation (Lally et al., 2016; Demjaha et al.,
2017). In terms of risk factors for developing TRS, demographic and clinical cor-
relates include male gender, early age at illness onset, poor premorbid functioning,
history of substance abuse, and a family history of schizophrenia (Huber, Gross,
Schüttler & Linz, 1980; Lieberman et al., 1993; Meltzer, Rabinowitz, Lee, Cola
et al., 1997; Lindenmayer, 2000; Lally et al., 2016).
Despite the fact that treatment resistance has been a consistent phenomenon
since the advent of antipsychotic medication, the pathophysiology of treatment
refractoriness remains unclear. Although it is widely accepted that clozapine has a
higher efficacy than conventional antipsychotic treatment in TRS, the mechanisms
by which its superiority takes effect are incompletely understood. There is a
great need for a more comprehensive understanding of the neural mechanisms
underlying TRS. This could lead to early identification of refractoriness through
predictive biomarkers and subsequent acceleration of clozapine initiation, as well
as to the informed development of research strategies into potential new avenues
for treatment of TRS.
1.2.3 Neuroimaging evidence in TRS
1.2.3.1 Structural imaging findings
One of the earliest observations of structural brain differences between remitted
and non-remitted patients with schizophrenia was made by K. L. Davis et al.
(1998), who reported increased ventricle size in poor-outcome patients using com-
puted tomography (CT), with a progressive course of further ventricular increase
over a 4 year span. The subsequent advances in neuroimaging techniques, notably
MRI, have lead to a proliferation of studies investigating brain structure in schizo-
phrenia as well as TRS specifically. Volumetric studies have shown decreases in
frontal and occipital grey matter volume in TRS patients compared to healthy
controls (Molina et al., 2008), as well as in widespread regions – particularly frontal
and temporal structures – compared to treatment responsive patients (Lawrie et
al., 1995; Quarantelli et al., 2014; Anderson, Goldstein, Kydd & Russell, 2015).
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These findings are in line with research showing that cortical grey matter volume
in first episode psychosis (FEP) is correlated with subsequent treatment response
(Zipursky, Zhang-Wong, Lambe, Bean & Beiser, 1998). Interestingly, grey mat-
ter volume reductions in medial frontal, insular, and bilateral temporal cortical
regions have been specifically linked to treatment resistant auditory verbal hallu-
cinations, suggesting a direct association between cortical volume and persistent
symptoms (Kubera et al., 2014). More widespread reductions in cortical thickness
have also been observed in TRS patients than in responsive patients compared
to healthy controls (Zugman et al., 2013; Ahmed et al., 2015), and response to
clozapine is associated with less cortical thinning over the course of treatment
(Ahmed et al., 2015).
In terms of white matter, a number of studies have observed reduced white matter
volume in TRS patients compared to healthy controls (Maller et al., 2012; Ahmed
et al., 2015; Anderson et al., 2015). In contrast, Molina et al. (2008) reported that
increased occipital and temporal white matter volume was predictive of treatment
resistance. In studying white matter integrity with diffusion weighted imaging,
Holleran et al. (2014) found widespread reductions of fractional anisotropy in the
corpus callosum and temporal lobe in clozapine-naive TRS patients compared to
healthy controls.
1.2.3.2 Functional imaging findings
A number of studies have focused on resting-state functional connectivity in TRS
compared to either healthy controls or treatment responsive patients. Two groups
specifically studied treatment-resistant auditory verbal hallucinations (AVH) in
relation to functional connectivity (Vercammen, Knegtering, den Boer, Liemburg
& Aleman, 2010; Alonso-Solís et al., 2015). Alonso-Solís et al. (2015) found that
patients with treatment resistant AVH showed increased functional connectivity
between the dorso-medial prefrontal cortex and bilateral precentral gyri, opercu-
lar, and insular cortices, but decreased functional connectivity between ventro-
medial prefrontal cortex and dorsal anterior cingulate cortex (ACC) compared
to non-hallucinating treatment responsive patients. Vercammen et al. (2010) re-
ported that in comparison to healthy controls, patients with treatment resistant
AVH had reduced functional connectivity between the temporal parietal junction
(TPJ) and Broca’s area, cortical regions associated with speech perception and
22
language production, respectively. In addition, connectivity between the TPJ and
ACC was negatively correlated with the severity of AVH.
In two elegant studies assessing striatal functional connectivity, Sarpal and col-
leagues showed that striatal connectivity with frontal and limbic regions increased
after 12 weeks of treatment with aripiprazole or risperidone, with treatment re-
sponse correlating with the degree of striato-parietal connectivity increase (Sarpal,
Robinson et al., 2015), and that baseline striatal connectivity can potentially be
used as a prognostic biomarker for treatment response (Sarpal, Argyelan et al.,
2015). In a further recent study, T. P. White et al. (2016) compared chronic treat-
ment resistant and responsive patients in terms of striatal connectivity patterns.
TRS patients showed reduced connectivity between ventral striatum and substan-
tia nigra, as well as between dorsal-caudal putamen and thalamus compared to
treatment responders. In contrast, there was increased functional connectivity
between the dorsal caudate and medial/superior prefrontal cortex in TRS pa-
tients, suggesting that striatal systems selectively differ as a function of treatment
response status.
There has been an increased effort in recent years to elucidate metabolic pro-
cesses in the brain in TRS. Demjaha et al. (2012) used F-DOPA Positron Emis-
sion Tomography (PET) imaging to assess striatal dopamine synthesis capacity
in treatment resistant and treatment responsive patients as well as healthy con-
trols. They found that patients who had responded well to treatment exhibited
higher dopamine synthesis capacity than both TRS patients and healthy con-
trols, providing the first evidence that TRS may not be characterised by the same
dopamine dysfunction typically associated with schizophrenia. In the same year,
Egerton et al. (2012) reported that FEP patients who were still symptomatic
after at least one course of antipsychotic treatment showed elevated glutamate
levels in the ACC compared to FEP patients who were in remission. This finding
was supported by subsequent studies showing elevated ACC glutamate in chronic
TRS patients compared to healthy controls (Demjaha et al., 2014) and treatment
responders (Mouchlianitis et al., 2015).
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1.2.3.3 Summary
Taken together, the available neuroimaging evidence suggests that treatment res-
istant and treatment responsive schizophrenia may be characterised by divergent
neuropathophysiologies. TRS is associated with greater abnormalities in cortical
structure as well as functional connectivity patterns, which may result in the
failure of conventional antipsychotics, targeting primarily the dopamine system,
to exert a therapeutic effect. Crucially, there is mounting evidence that TRS
may not exhibit a dopaminergic dysfunction at all or to the same extent as treat-
ment responsive schizophrenia. However, despite the proliferation of neuroimaging
studies in TRS, only few of these studies directly compare treatment resistant and
treatment responsive patients, particularly prior to clozapine initiation. Due to
the differential effects of clozapine on the brain compared to conventional an-
tipsychotics (Navari & Dazzan, 2009), clozapine exposure remains a potential
confounder in many studies. Furthermore, stringency of definitions of TRS varies
widely throughout the literature and a number of studies do not include a sample
of treatment responsive patients. While a pattern of exacerbated functional dys-
connectivity in TRS is emerging, functional neuroimaging studies overwhelmingly
utilise resting-state fMRI without taking into account task-related activation pat-
terns. Given the availability of a vast array of cognitive behavioural paradigms
which have been widely implemented in schizophrenia research, explicit compar-
isons of patient subgroups in terms of both behaviour and task-related brain
function may provide valuable insights into the neural mechanisms underlying
treatment response in psychosis.
1.3 Cognitive control in schizophrenia
1.3.1 Mechanisms of cognitive control
In everyday life we are regularly confronted with a complex set of demands which
compete for attention and adequate behavioural responses. The ability to flex-
ibly adapt attention in response to these demands and guide behaviour towards
relevant goals, while inhibiting task-irrelevant behaviour, is broadly included in
the concept of cognitive control. Cognitive (or executive) control plays an im-
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portant role in a wide array of higher cognitive domains, including episodic and
working memory, flexible learning, task switching, response inhibition, and emo-
tion regulation (Cohen, Braver & O’Reilly, 1996; Banich et al., 2000; Ochsner &
Gross, 2005; Ranganath, Minzenberg & Ragland, 2008; Ragland et al., 2009). As
such it requires the intact functioning of a number of sub-processes such as goal
representation, update, and maintenance; conflict monitoring; stimulus-response
mapping; and response selection (Ridderinkhof, Van Den Wildenberg, Segalowitz
& Carter, 2004). Cognitive control thus underlies much of the remarkable ability
of humans to adapt flexibly to fluctuating daily challenges. Accordingly, cognit-
ive control is subserved by a widely distributed network in the brain and can be
probed with a large variety of behavioural paradigms. Functional abnormalities
within distinct components of the underlying network are thought to manifest in
dysfunctions in different aspects of control-related behaviour.
Mounting evidence indicates the importance of aspects of the salience network,
including the anterior cingulate cortex (ACC) and anterior insula, working in
concert with a fronto-parietal network spanning the dorsolateral prefrontal cortex
(DLPFC), ACC, and parietal cortex, in order to coordinate flexible adaptation
to contextual demands (S. K. Peters, Dunlop & Downar, 2016; McTeague et
al., 2017). Recent meta-analytical findings suggest that executive functioning is
subserved by a superordinate fronto-parietal cognitive control network (Minzen-
berg, Laird, Thelen, Carter & Glahn, 2009; Niendam et al., 2012), with vari-
ation in additional task-specific recruitment of other cortical and subcortical re-
gions. Connectivity with subcortical nodes of the salience network in the striatum,
thalamus, and brainstem forms discrete cortico-striatal-thalamic-cortical (CSTC)
loops which are thought to play a key role in cognitive control (S. K. Peters et al.,
2016). Abnormalities of cognitive control related networks have been observed
across a range of psychiatric illnesses, whereby the exact localisation and severity
of the disruption differ between diagnoses (McTeague et al., 2017).
1.3.2 Cognitive control deficits in schizophrenia
Cognitive deficits are a consistent feature of schizophrenia. Many cognitive func-
tions which rely on executive control are impaired in the illness and these impair-
ments are thought to contribute to poor functional outcomes (Green, Kern, Braff
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& Mintz, 2000). In addition, symptoms of psychosis can be understood in terms
of concepts relevant to cognitive control, namely deficits in the flexible, adaptive
control of thoughts and behaviour, as well as a difficulty in separating relevant
from irrelevant environmental stimuli.
On a behavioural level, patients with schizophrenia exhibit a failure to exert
cognitive control adequately in a number of tasks, such as the Stroop task. The
Stroop task is a standard measure of cognitive inhibition, whereby performance
relies on the suppression of a prepotent response elicited by stimulus interference.
Specifically, the task requires naming of the font colour of a printed colour word,
whereby the word and font colour can be congruent (e.g., the word “blue” written
in blue) or incongruent (e.g. the word “blue” written in yellow). On incongruent
trials, respondents have to overcome the prepotent reading response in favour
of the more difficult colour naming task by exerting cognitive control. Patients
with schizophrenia typically show a greater interference effect in terms of both
reaction time and accuracy, as confirmed by a recent meta-analysis (Westerhausen,
Kompus & Hugdahl, 2011), although the presence and extent of the dysfunction
appears to depend on the experimental setup of the task (Henik & Salo, 2004).
Behavioural deficits in cognitive control are also commonly observed in schizo-
phrenia on other measures of executive functioning, pointing towards an over-
arching impairment in control related processes (Minzenberg et al., 2009; Lesh,
Niendam, Minzenberg & Carter, 2011). For example on the Wisconsin Card Sort-
ing Test (WCST), a set-shifting task which requires flexible responding in the face
of contingency changes, patients with schizophrenia typically display increased
perseverative responding and require more trials to reach a performance criterion
compared to healthy controls (Berman, Zec & Weinberger, 1986; Weinberger, Ber-
man & Zec, 1986; Braff et al., 1991; Everett, Lavoie, Gagnon & Gosselin, 2001;
Prentice, Gold & Buchanan, 2008). Furthermore, schizophrenia has been con-
sistently associated with working memory deficits (Goldman-Rakic, 1994; Glahn
et al., 2005; Manoach, 2003). The link between cognitive control and working
memory has been extensively reviewed and is evident in the role of executive con-
trol in maintaining task-relevant information in working memory and protecting
it against sources of interference. Research suggests that working memory deficits
in schizophrenia may be due to a failure of active goal maintenance in control-
related circuits (Braver, Gray & Burgess, 2007). More classical tasks of cognitive
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control and inhibition such as the Go/NoGo task (Weisbrod, Kiefer, Marzinzik
& Spitzer, 2000), Eriksen flanker task (Sambataro et al., 2013), and Continuous
Performance Test (Chen & Faraone, 2000), are also sensitive to behavioural defi-
cits in patients with schizophrenia. In light of these collective findings, cognitive
control has been proposed as a unifying theory for higher cognitive dysfunctions
in schizophrenia (Lesh et al., 2011).
1.3.3 Neural correlates of cognitive control deficits in schizo-
phrenia
The observed behavioural effects are mirrored in neural abnormalities in networks
relevant to cognitive control in schizophrenia, most commonly reflected in reduced
activation of prefrontal cortical areas (Lewis & Anderson, 1995; Glahn et al.,
2005). Hypoactivation of the DLPFC during the WCST was reported in an early
study by Weinberger et al. (1986), which has since been repeatedly observed
during several other cognitive controls tasks (Barch et al., 2001; Perlstein, Carter,
Noll & Cohen, 2001; MacDonald et al., 2005; Snitz et al., 2005; Weiss et al.,
2007; Yoon et al., 2008). Furthermore, reduced ACC activation in schizophrenia
is commonly reported both for the Stroop task (Carter, Mintun, Nichols & Cohen,
1997; Yücel et al., 2002; Kerns et al., 2005; Weiss et al., 2007) as well as other
tasks involving error monitoring or response inhibition (Rubia et al., 2001; Carter,
MacDonald, Ross & Stenger, 2001; Laurens, Ngan, Bates, Kiehl & Liddle, 2003;
Ford et al., 2004; Polli et al., 2007).
Interestingly, a meta-analysis in FEP patients showed reduced ACC activations
across a range of cognitive tasks, suggesting that functional abnormalities in this
area manifest at an early stage of the illness (Radua et al., 2012). In contrast,
unaffected first-degree relatives of patients with schizophrenia showed impaired
DLPFC functioning, but an intact ACC response during the Stroop task, point-
ing towards an illness-specific role for ACC functioning in schizophrenia (Becker,
Kerns, MacDonald & Carter, 2008). The DLPFC and ACC are the key frontal
nodes involved in exerting active executive control. DLPFC has been suggested
to regulate goal representation, maintenance, and updating, while ACC plays a
role in conflict detection, conveying this information back to DLPFC, which in
turn modulates goal-directed behaviour in a top-down fashion (MacDonald, Co-
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hen, Stenger & Carter, 2000). Abnormal recruitment of these areas appears to
underlie the observed behavioural deficits and is associated with increased symp-
tom severity in schizophrenia (Goghari, Sponheim & MacDonald, 2010; Edwards,
Barch & Braver, 2010; Fornito, Yoon, Zalesky, Bullmore & Carter, 2011). A com-
prehensive meta-analysis of executive function deficits in schizophrenia confirmed
a consistent hypoactivation of DLPFC and ACC, as well as thalamus and pos-
terior temporal and parietal areas (Minzenberg et al., 2009). In addition, there is
a consistent pattern of hyperactivation in medial frontal areas subtending midcin-
gulate and presupplementary motor cortices (Minzenberg et al., 2009; McTeague
et al., 2017), which may reflect a compensatory response in patients performing
at a similar level as healthy controls.
Connectivity within CSTC loops also plays a key role in cognitive control processes
and evidence from several lines of research suggests that both structural and func-
tional abnormalities within these circuits contribute to cognitive deficits in schizo-
phrenia (Frith & Done, 1988; Andreasen et al., 1997; Eisenberg & Berman, 2010).
Rubia et al. (2001) observed increased activation of the thalamus and putamen
during an inhibition task with simultaneous DLPFC hypoactivation, although hy-
peractivity of the basal ganglia in the context of normal prefrontal functioning
has also been reported (Kawasaki et al., 1992). In an influential study, Meyer-
Lindenberg et al. (2002) studied striatal presynaptic dopamine synthesis as well
as prefrontal activation during the WCST in unmedicated patients and healthy
controls. They found exaggerated presynaptic dopaminergic function as well as
reduced task-related DLPFC activation in patients compared to healthy controls.
These measures were significantly correlated in patients, but not in controls, sug-
gesting that the subcortical dopaminergic dysfunction may arise as a result of pre-
frontal hypoactivation. This notion converges with formulations of the dopamine
hypothesis of schizophrenia, which posits that reduced cortical activation caused
by prefrontal hypodopaminergia results in excess dopaminergic transmission in the
striatum (K. L. Davis, Kahn et al., 1991). However, importantly, the most recent
version of the hypothesis stresses that this is only one of several possible pathways
leading to subcortical hyperdopaminergia (Howes & Kapur, 2009), which in turn
is thought to result in a state of aberrant salience whereby salience is randomly
assigned to irrelevant environmental stimuli. In the context of cognitive control,
the basal ganglia have been suggested to provide a gating mechanism, regulating
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the flow of relevant information into working memory (Frank, Loughry & O’Reilly,
2001a). As such, elevated subcortical dopamine levels are likely to increase the
potential for irrelevant distracting stimuli to “pass” the gate and be processed
by prefrontal cortex, which would manifest as a failure of response inhibition or
directed attention. In a direct test of this hypothesis, Ceaser and Barch (2015)
showed that patients’ striatal activity, when incorrectly responding to distracter
stimuli during a cognitive control task, was significantly related to aberrant sa-
lience symptoms. In this modified match-to-sample task, subjects encoded two
abstract symbols and were subsequently presented with a third symbol: either a
distracter which was to be ignored, or an update symbol which was to replace one
of the previously encoded stimuli. Importantly, prefrontal and striatal activation
was increased compared to healthy controls when patients incorrectly encoded a
distracter, but decreased when they failed to update a new symbol in working
memory. These findings highlight the complex nature of reciprocal fronto-striatal
connections involved in cognitive control.
1.3.4 Implications for TRS
Taken together, converging evidence suggests that disturbances in dynamic cortical-
subcortical and fronto-parietal networks underlie cognitive control deficits in schizo-
phrenia. Limited evidence suggests that antipsychotic medication may improve
neural activation during cognitive tasks; however, the relationship to symptomatic
treatment response is unclear (Kani, Shinn, Lewandowski & Öngür, 2017). For
example, Snitz et al. (2005) demonstrated improved DLPFC and ACC functioning
on an inhibition task after four weeks of antipsychotic treatment, but no associ-
ation with symptom change was observed. Similarly, DLPFC activation during
a working memory task has been shown to increase with antipsychotic treatment
(Honey et al., 1999; Schlagenhauf, Wüstenberg et al., 2008), but symptoms did
not improve significantly in these studies. Meisenzahl et al. (2006) reported that
ventrolateral prefrontal cortex activation increased after 12 weeks of atypical anti-
psychotic treatment on a 2-back task; this change was accompanied by a signific-
ant improvement in symptoms. Symptom change after 6-8 weeks of antipsychotic
treatment was furthermore shown to be significantly associated with increased
activation in the inferior frontal junction during a Stroop task (Krabbendam et
al., 2009). Van Veelen et al. (2011) divided patients into responders and non-
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responders after 10 weeks of receiving antipsychotic medication. While there was
no change in DLPFC function after treatment on a working memory task, non-
responders showed a reduced practice effect over time compared to responders
and healthy controls. However, to date no study has explicitly investigated differ-
ences in neural activation related to cognitive control tasks in treatment resistant
and treatment responsive patients as defined using strict criteria of TRS. It is
possible that subtle differences in cortical-subcortical interactions between these
patient groups would lead to a differential impact of antipsychotic medication on
cognitive and neural function. Given that antipsychotic treatment response is as-
sociated with increased resting-state connectivity of the midbrain with ACC and
thalamus (Hadley et al., 2014), it seems likely that TRS patients would benefit
to a lesser degree from antipsychotic medication in terms of improving cognitive
control function.
1.4 Reinforcement learning in schizophrenia
1.4.1 Mechanisms of reinforcement learning
Central to human decision making is the ability to choose actions contingent on
the environment which will yield a rewarding outcome. Adaptive functioning in
a highly dynamic surrounding relies on ongoing learning processes, whereby the
consequences of actions are utilised to inform future behaviour so as to achieve
long-term gain. Learning mechanisms are intimately linked with cognitive control
mechanisms, both conceptually and neurobiologically (Holroyd & Coles, 2002;
Ridderinkhof et al., 2004; Boehler et al., 2011; Collins & Frank, 2013). Just as
cognitive control involves distinguishing between relevant and irrelevant stimuli
and guiding behaviour toward task-relevant goals, learning from feedback implies
separating rewarding from non-rewarding outcomes and reinforcing behaviour that
leads to reward. It is therefore unsurprising that feedback learning mechanisms
are for a large part underpinned by similar cortical-subcortical circuits which are
implicated in cognitive control (Holroyd & Coles, 2002; Botvinick, 2007; Collins
& Frank, 2013).
The mesencephalic dopamine system in particular plays an important role in re-
ward processing, the current understanding of which was heavily influenced by
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seminal studies conducted by Schultz and colleagues (Romo & Schultz, 1990;
Schultz, Apicella, Scarnati & Ljungberg, 1992; Schultz, Apicella & Ljungberg,
1993; Mirenowicz & Schultz, 1994, 1996; Schultz, 1998). Using single cell record-
ing in monkeys, Schultz and colleagues demonstrated that midbrain dopamine
neurons show phasic activation in response to rewarding stimuli, and a phasic de-
crease in activation in response to aversive stimuli. Crucially, however, when the
stimulus is preceded by a conditioned predictive cue, dopamine neurons respond
to the cue rather than to the reward stimulus itself (Schultz, 1998). Consequently,
predictable rewards do not elicit a dopamine response and omission of predicted
rewards results in a negative response. The implication is that midbrain dopamine
does not, as previously thought (Berridge, 2004), code for primary reward itself,
but rather for deviations from predictions about reward, or reward prediction
error (RPE) (Schultz & Dickinson, 2000; Bayer & Glimcher, 2005; Maia, 2009).
Dopaminergic RPE signalling is thought to act as a learning signal which is fed
back to the prefrontal cortex via the basal ganglia in order to adjust behaviour
accordingly, increasing go behaviour which leads to reward, and suppressing no-
go behaviour which leads to aversive outcomes (Hikida, Kimura, Wada, Funabiki
& Nakanishi, 2010; Maia & Frank, 2011). Computational modelling of reinforce-
ment learning behaviour, in combination with functional neuroimaging, allows for
the identification and localisation of neural activation correlating with RPE in hu-
mans (Garrison, Erdeniz & Done, 2013). Indeed, RPE-related activation during
reinforcement learning tasks is typically observed in the striatal projection targets
of dopaminergic neurons, notably the ventral striatum (Pagnoni, Zink, Montague
& Berns, 2002; McClure, Berns & Montague, 2003; O’Doherty, Dayan, Friston,
Critchley & Dolan, 2003; Pessiglione, Seymour, Flandin, Dolan & Frith, 2006;
Bray & O’Doherty, 2007).
Cortical nodes of the reward network, including the orbitofrontal cortex (OFC),
DLPFC, and ACC, are thought to represent to varying extents the value of anti-
cipated outcomes. Specifically, OFC has been shown to represent stimulus reward
value for both primary (O’Doherty et al., 2003; Small et al., 2003) and secondary
(Elliott, Newman, Longe & Deakin, 2003; Hare, O’Doherty, Camerer, Schultz &
Rangel, 2008) reward stimuli and is particularly implicated in flexible learning
under changing reward contingencies in the environment (John O’Doherty, Krin-
gelbach, Rolls, Hornak & Andrews, 2001; Fellows & Farah, 2003; Clark, Cools &
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Robbins, 2004). Thus, OFC dysfunctions are associated with deficits in reversal
learning tasks (John O’Doherty et al., 2001; Fellows & Farah, 2003). In line with
its role in cognitive control function, DLPFC is thought to regulate executive func-
tions necessary for reinforcement learning, such as attention (Hornak et al., 2004)
and working memory (D. Lee & Seo, 2007), although it has also been shown to
be involved in reward value representation (Knutson, Taylor, Kaufman, Peterson
& Glover, 2005; Seo, Barraclough & Lee, 2007). The conflict-monitoring activ-
ity of ACC is implicated in reinforcement learning specifically for no-go learning,
whereby ACC receives dopaminergic negative reinforcement signals from the mid-
brain and guides behaviour through avoidance-learning mechanisms (Holroyd &
Coles, 2002; Botvinick, 2007). ACC function appears to be most involved in the
early stages of learning, when conflict is arguably highest (Bussey, Muir, Everitt
& Robbins, 1996; Bush et al., 1998). In addition, RPE signalling has been ob-
served in all of these cortical regions both in animal (Tremblay & Schultz, 2000;
Buch, Brasted & Wise, 2006; Matsumoto, Matsumoto, Abe & Tanaka, 2007) and
human (Nobre, Coull, Frith & Mesulam, 1999; O’Doherty et al., 2003; Schultz
& Dickinson, 2000; Behrens, Woolrich, Walton & Rushworth, 2007) studies, al-
though the interpretation of cortical RPE signalling remains a subject of debate
(Niv & Schoenbaum, 2008).
1.4.2 Reinforcement learning deficits in schizophrenia
Learning mechanisms have been central to research on schizophrenia due to the
relevance of dopamine both to reward processing and psychosis. Indeed schizo-
phrenia has long been understood to involve reduced or disordered reward-motivated
behaviour (Kraepelin, 1921; Bleuler, 1950; Barch, 2008), an observation which
has been associated naturally with the prevalence of anhedonia in schizophrenia
(Barch & Dowd, 2010). However, research shows that patients with schizophrenia
do not show reduced sensitivity to reward itself or a lack of hedonic experiences
(Kring, Kerr, Smith & Neale, 1993; Heerey & Gold, 2007; Burbridge & Barch,
2007). Instead, it has become increasingly clear that abnormal reward processing
in schizophrenia is associated with a deficit in learning from feedback (Barch &
Dowd, 2010; Strauss, Waltz & Gold, 2013). In particular, patients with schizo-
phrenia exhibit impaired learning on probabilistic reinforcement learning tasks
(Waltz, Frank, Wiecki & Gold, 2011; Waltz & Gold, 2007). These behavioural
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deficits are variably attributed to impairments in representing and updating pre-
dicted reward values or impairments in generating reward prediction errors in re-
sponse to feedback. In a computational modelling approach to tease apart these
two mechanisms, Gold et al. (2012) showed that patients with schizophrenia
with pronounced negative symptoms showed impairments in learning to obtain
gains, but relatively intact learning to avoid losses. Crucially, when asked to
choose between a potential gain stimulus and potential loss-avoidance stimulus in
a transfer phase, the same patients failed to prefer the stimulus with the overall
higher expected value. These findings suggest that negative symptoms are associ-
ated with normal generation of prediction errors (since loss-avoidance learning was
intact), but an inability to correctly represent the overall reward value of stimuli.
Also consistent with abnormal reward value representation are dysfunctions in
rapid adjustment to contingency changes, as evidenced in reversal learning tasks
(Waltz & Gold, 2007). More recently it has been suggested that the failure to
represent reward value may be accounted for by working memory deficits (Collins,
Albrecht, Waltz, Gold & Frank, 2017). Support for dysfunctional prediction error
generation comes predominantly from the neuroimaging literature, as discussed
below.
Overall, there is consistent evidence that patients with schizophrenia are impaired
in go learning with relatively preserved no-go learning. For example, Waltz,
Frank, Robinson and Gold (2007) reported impaired reinforcement learning for
rewarding stimuli with normal avoidance of the most negative stimuli. Further-
more, by explicitly modelling learning rates for gain-related and loss-related stim-
uli, Dowd, Frank, Collins, Gold and Barch (2016) demonstrated significantly lower
gain learning rates in patients with schizophrenia compared to healthy controls,
but similar loss learning rates. These findings are consistent with the notion of
increased tonic dopamine activity in the midbrain (known to enhance no-go learn-
ing) but decreased phasic firing to behaviourally relevant stimuli (necessary for
intact go learning). Importantly however, not all studies have reported impaired
learning behaviour in schizophrenia (Gold, Hahn, Strauss & Waltz, 2009; Graham
K Murray, Corlett & Fletcher, 2010), and learning seems to be spared in relatively
simple reinforcement learning tasks (Weinberger, Berman & Frith, 1996).
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1.4.3 Neural correlates of reinforcement learning deficits
in schizophrenia
There is an abundance of neuroimaging studies examining the neural correlates of
reinforcement learning in schizophrenia; however, studies vary widely in their
tasks, patient sample characteristics, and the specific aspect of reinforcement
learning that was the focus of the study. There is relative consistency in the evid-
ence concerning reward anticipation, for which decreased ventral striatal activity
has been observed in unmedicated patients with schizophrenia (Juckel, Schlagen-
hauf, Koslowski, Wüstenberg et al., 2006; M. O. Nielsen, Rostrup, Wulff, Bak,
Lublin et al., 2012; Schlagenhauf et al., 2009) and first episode psychosis (Ess-
linger et al., 2012). A recent meta-analysis of 23 studies confirmed the presence
of a strong ventral striatum hypoactivation during reward anticipation in schizo-
phrenia (Radua et al., 2015). Consistent with behavioural findings, the atten-
uation of striatal reward-related activation is attributed to an overall increase
in tonic dopamine activity in combination with decreased phasic reward elicited
firing (Heinz & Schlagenhauf, 2010).
In contrast, the literature on feedback processing in schizophrenia is less consistent
(Maia & Frank, 2017). Several studies have reported reduced RPE signalling in
schizophrenia and FEP patients compared to healthy controls in both subcortical
(G. Murray et al., 2008; Schlagenhauf et al., 2009; Waltz et al., 2009; Koch et
al., 2010; Gradin et al., 2011; Schlagenhauf et al., 2014) and cortical (Corlett
et al., 2007; Koch et al., 2010; G. Murray et al., 2008) structures; whereas other
studies have found normal RPE signalling in patients (Dowd et al., 2016; Culbreth,
Westbrook, Xu, Barch & Waltz, 2016). It has been suggested that discrepancies
may be due to differences in the inclusion of medicated and unmedicated patients
into studies and that antipsychotic medication normalises the RPE response in
patients (Culbreth et al., 2016). However, this interpretation is at odds with the
finding of abnormal RPE activation in medicated patients (Corlett et al., 2007;
G. Murray et al., 2008; Waltz et al., 2009; Gradin et al., 2011).
Abnormal RPE signalling in schizophrenia has been shown in several studies to
arise as a result of blunted responses to unexpected reward as well as augmented
responses to predictable reward (Corlett et al., 2007; Waltz et al., 2009; Morris
et al., 2012). Interestingly, there is converging evidence that patients with schizo-
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phrenia show intact RPE signalling in response to losses (negative RPEs), but
blunted activation in response to wins (positive RPEs), a result which is consist-
ent with behavioural findings of selectively impaired go-learning in schizophrenia
(Waltz et al., 2009; Koch et al., 2010; Waltz et al., 2010; Simon et al., 2010).
Furthermore, blunted responses to reward outcomes has been related to negat-
ive symptoms such as anhedonia (Dowd et al., 2016) and avolition (Waltz et al.,
2009), as well as positive symptoms (Culbreth et al., 2016; Schlagenhauf et al.,
2009; Corlett et al., 2007; Gradin et al., 2011). A meta-analysis of ventral striatal
RPE-related activation including 8 studies could only establish hypoactivation
in patients at trend level, with no consistent relationship observed with symp-
tom dimensions (Radua et al., 2015). Taken together, there is tentative evidence
to suggest that abnormal prediction error signalling may contribute to reinforce-
ment learning deficits as well as symptom formation in schizophrenia, although
considerable inconsistencies remain regarding the localisation and extent of the
dysfunction.
Besides abnormal generation of RPE signals, reinforcement learning processes may
arise due to a failure to update reward value representations on a trial-by-trial
basis. This rapid process is underpinned by prefrontal areas, in particular OFC. It
has been suggested that OFC dysfunction in schizophrenia may result in impaired
representation of reward value, as well as an inability to utilise feedback informa-
tion to rapidly update this representation (Gold et al., 2008). Behavioural findings
of impaired reversal learning (Elliott, McKenna, Robbins & Sahakian, 1995; Pan-
telis et al., 1999), which is known to be underpinned by OFC functioning (Cools,
Clark, Owen & Robbins, 2002; Hornak et al., 2004; Waltz & Gold, 2007), have
been interpreted as an indicator of OFC dysfunction in schizophrenia (Waltz &
Gold, 2007). More recently neuroimaging studies have indeed reported abnor-
mal frontal activation during probabilistic reversal learning (Waltz et al., 2013;
Culbreth et al., 2016).
In summary, converging evidence suggests that patients with schizophrenia show
reinforcement learning deficits which are underpinned by dysfunctions of the un-
derlying neural reward network. These are largely attributed to abnormalities
in the subcortical dopamine system, with elevated baseline levels of dopamine in
combination with attenuated response of dopamine neurons to reward anticipa-
tion and receipt resulting in blunted activation patterns in patients as compared
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to healthy controls. In addition, prefrontal hypofunction – potentially mediated
by reduced dopamine in the prefrontal cortex – results in abnormal processing of
reward feedback and representation of stimulus values. This dysfunction is likely
to contribute to the development of psychotic symptoms such as delusions, due to
a failure to accurately represent and update expectations of the environment, as
well as anhedonia and avolition due to the inability to anticipate reward outcomes
adequately.
1.4.4 Implications for TRS
Very little is known about how antipsychotic treatment response relates to re-
inforcement learning deficits and their underlying neural impairments in schizo-
phrenia. However, reinforcement learning tasks may provide a particularly useful
tool for elucidating the mechanisms underlying treatment response in psychosis, as
they tap into various facets of cognitive processing and neural functioning which
could be differentially implicated in patient subgroups.
Few studies have explicitly studied the effect of antipsychotic medication on re-
ward processing. In examining the differential effect of first and second generation
antipsychotics on reward anticipation, Juckel, Schlagenhauf, Koslowski, Filonov
et al. (2006) reported that patients currently taking first generation antipsychotics
showed an absence of ventral striatal activation, whereas patients taking second
generation antipsychotics showed a normal response similar to healthy controls
while anticipating reward. Similarly, in a longitudinal study, Schlagenhauf, Juckel
et al. (2008) were able to show that the blunted ventral striatal activation in pa-
tients on first generation antipsychotics was subsequently normalised after the
same patients were switched to second generation antipsychotics. However, it is
unclear whether psychotic symptom change was related to this change in activa-
tion. Instead, blunted activation in patients on typical antipsychotics was signi-
ficantly related to negative symptomatology in both studies. In contrast, M. O.
Nielsen, Rostrup, Wulff, Bak, Broberg et al. (2012) compared ventral striatal ac-
tivation during reward anticipation in antipsychotic naive FEP patients before
and after 6 weeks of antipsychotic medication and found that an improvement in
psychotic symptoms was correlated with a normalisation of the previously blunted
neural response. However no data on RPE signalling was presented. Insel et al.
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(2014) recently reported that medication dosage correlated negatively with RPE
response in patients with schizophrenia; however, it remains unclear how this ef-
fect relates to treatment response. Medication dosage was not related to symptom
severity in this study, hence it is possible that highly medicated patients included
both those who responded well to this high dosage, and those who were resistant
to treatment and thus prescribed higher doses, as is typically observed. Notably,
in a study reporting relatively intact RPE signalling in medicated patients at the
group level (Culbreth et al., 2016), RPE activation was positively correlated with
positive symptoms, suggesting that the most unwell patients showed the strongest
RPE response despite antipsychotic treatment. This is in line with the notion that
treatment resistant schizophrenia may not be characterised by a dopaminergic ab-
normality to the same extent as treatment responsive schizophrenia.
As such, it is possible that the reported inconsistencies regarding reward feedback
in schizophrenia are a result of combining different neurobiological subgroups of
the illness within individual studies. Specifically, it is possible that neural signa-
tures related to subcortical dopamine functioning (i.e., RPE signalling) may be
more abnormal in patients who respond well to antipsychotic medication, whereas
TRS patients may show a non-dopaminergic dysfunction which results in similar
behavioural impairments. For example, if prefrontally modulated cognitive con-
trol mechanisms are more severely impaired in these patients, this may result in
an inability to adequately make use of otherwise intact reward prediction error
signals.
1.5 White matter connectivity in schizophrenia
1.5.1 White matter changes in schizophrenia
Ever since the earliest formulations of schizophrenia as a disorder of the brain,
there has been a conceptual understanding of the illness as one characterised by a
lack of coordination, or integration, of cognitive and perceptual functions (Bleuler,
1950). With an improved understanding of the neurobiology and phenomenology
of the illness in recent years, schizophrenia is increasingly described in terms of
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a dysconnection syndrome (Friston & Frith, 1995; Stephan et al., 2009; Friston
et al., 2016). Neural dysconnectivity leading to impaired communication between
distributed cortical, subcortical, and cerebellar regions is thought to play a major
role in the formation and maintenance of symptoms of psychosis as well as negative
symptoms. The dysfunction likely arises due to dysconnectivity at the level of the
synapse (Friston et al., 2016), as well as abnormal structural integrity of the
axonal projections connecting these brain regions (K. L. Davis et al., 2003).
Neuronal axons are insulated in lipid sheaths of myelin formed by oligodendroglia,
giving axon fibre bundles their brightness in MR images. Myelin increases the
conduction velocity of action potentials propagating along the axon, facilitating
fast communication within and between distributed neural networks. Although
myelination begins prenatally in humans, many major tracts undergo continued
myelination throughout childhood and adolescence, reaching their peak in early
adulthood (Lenroot & Giedd, 2006). Age-related reductions in myelination are
typically not observed until the age of 40 (Bartzokis et al., 2001). Converging
evidence from a number of research modalities supports myelin abnormalities as
a core pathophysiology of schizophrenia (K. L. Davis et al., 2003).
Neuroimaging research has most commonly assessed white matter using diffusion
weighted imaging, applying the diffusion tensor model to determine the direction-
ality of diffusing water molecules in each voxel (Karlsgodt, 2016). Diffusion can
be restricted along the axis of structured tissue such as fibre bundles, or occur
isotropically in all directions. Accordingly, the typically reported measure in dif-
fusion tensor imaging (DTI) studies is fractional anisotropy (FA), which indicates
the extent to which water molecules are anisotropically diffusing along the axis of
white matter tracts. FA is thus utilised as a proxy for white matter tract integ-
rity, which may correspond to a number of measures such as myelination, axon
membrane integrity, fibre density, axon diameter, or number. Most commonly FA
is interpreted in terms of myelination.
There is strong evidence for reduced FA in schizophrenia throughout the brain,
although there remains substantial variability in the extent and regional spe-
cificity of the disruption (Fitzsimmons, Kubicki & Shenton, 2013). The most
frequently reported regions of decreased FA in patients with schizophrenia com-
pared to healthy controls include the frontal and temporal lobes as well as their
connecting tracts, such as the superior and inferior longitudinal fasciculi (Hatton
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et al., 2014; Caprihan et al., 2011; Sasamoto et al., 2013; Hoptman et al., 2008;
Lener et al., 2014), uncinate fasciculus (Maniega et al., 2008; De Weijer et al.,
2011; Boos et al., 2013; Sasamoto et al., 2013), arcuate fasciculus (De Weijer et al.,
2011; Maniega et al., 2008), and the cingulum bundle (Skelly et al., 2008; Hao et
al., 2006). The corpus callosum, connecting the two cerebral hemispheres, as well
as the internal capsule and cerebellar peduncles have also been frequently implic-
ated (Schneiderman et al., 2009; Roalf et al., 2013; Lener et al., 2014; Sasamoto
et al., 2013; Maniega et al., 2008; Hu Liu, Fan, Xu & Wang, 2011).
While several studies have only found focal differences in a few of these re-
gions, more recent research on larger samples suggests that the disruption may be
widespread and affect the majority of white matter tracts throughout the brain
(Klauser et al., 2017). Given the heterogeneity of symptom profiles in schizo-
phrenia, it is furthermore likely that different neurobiological subtypes of myelin
dysfunction exist. Indeed, two studies have recently demonstrated that differ-
ent patterns of FA reductions are associated with different symptom subgroups
(Arnedo et al., 2015; H. Sun et al., 2015). Interestingly, one of the few studies
reporting FA increases in schizophrenia found that patients experiencing hallu-
cinations had increased FA in the lateral part of the arcuate fasciculus compared
to patients without hallucinations and healthy controls (Hubl et al., 2004). This
is particularly interesting given the role of this portion of the arcuate fasciculus
in connecting frontal speech production areas with temporal auditory and speech
perception areas.
White matter disruptions have also been observed in FEP patients; however there
is less consistency of results in these samples. Reduced FA has been observed in
FEP in frontal and temporal tracts as well as the corpus callosum (Price et al.,
2007; Cheung et al., 2011; Melicher et al., 2015; Q. Wang et al., 2011), whereas
other studies have found no difference between FEP patients and healthy controls
(T. White et al., 2009; Moriya et al., 2010; Kong et al., 2011; B. D. Peters et al.,
2008). However, where FA reductions are reported, the affected regions appear
to be subsets of those often implicated in chronic schizophrenia (Di Biase et al.,
2017). It has thus been argued that white matter abnormalities begin in part
early on in the illness and take a progressive course thereafter. Nevertheless, a
remaining confounder in the association of white matter abnormalities with ill-
ness progression is antipsychotic medication, which has been found to cause both
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increases and decreases in myelin (Bartzokis et al., 2007; Bartzokis et al., 2012;
Ho, Andreasen, Ziebell, Pierson & Magnotta, 2011; Q. Wang et al., 2013; Ozcelik-
Eroglu et al., 2014). It is unclear to what extent cumulative antipsychotic med-
ication over the lifespan may contribute to white matter abnormalities in chronic
schizophrenia; however findings of white matter abnormalities in medication-naive
patients lend support for a disease-related deterioration of white matter tracts (X.
Liu et al., 2014; Mandl et al., 2013). Fronto-temporal and fronto-limbic abnormal-
ities have also been observed in individuals at ultra-high risk (UHR) for psychosis
(Vijayakumar et al., 2016), with the extent of FA reductions showing an asso-
ciation with functional deterioration (Karlsgodt, Niendam, Bearden & Cannon,
2009) and conversion to psychosis (Carletti et al., 2012).
Thus, DTI studies provide overwhelming evidence for widespread white matter
disruptions in schizophrenia, which are typically taken as indicators of a myelin-
related dysfunction. These findings converge with genetic data showing that oli-
godendroglial and myelin related genes are associated with schizophrenia risk, as
evidenced in numerous candidate gene studies (N. Takahashi, Sakurai, Davis &
Buxbaum, 2011) as well as genome wide association studies, albeit to a lesser
extent (Roussos & Haroutunian, 2014). In addition, gene expression studies in
postmortem brains have found downregulation of genes related to oligodendro-
cytes and myelin in DLPFC, cingulate cortex, superior temporal gyrus, and hip-
pocampus (Hakak et al., 2001; Aston, Jiang & Sokolov, 2004; Dracheva et al.,
2006; Katsel, Davis & Haroutunian, 2005). There is some evidence for an asso-
ciation between neuroinflammation and white matter pathology in schizophrenia
(Najjar & Pearlman, 2015); however, the directionality of a potential causal re-
lationship between the two remains unclear. Within neuroimaging research, the
importance of moving beyond FA based assessments has been noted (Karlsgodt,
2016). While FA constitutes a sensitive measure of white matter abnormalities, it
is not specific to myelin content. As such, there is a need to combine these efforts
with more sophisticated myelin imaging techniques, enabling a more detailed un-
derstanding of the microstructural changes involved in white matter pathology in
schizophrenia.
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1.5.2 Implications for TRS
Numerous studies have attempted to elucidate the association between antipsychotic
medication, treatment response, and white matter changes in schizophrenia. There
is early evidence that white matter abnormalities may serve as a potential bio-
marker for treatment resistance; however the complexity of the association has
resulted in several inconsistent findings.
Research has shown that antipsychotic medication increases intracortical myelin
(ICM) and white matter volume in patients with FEP (Bartzokis et al., 2011;
Bartzokis et al., 2012), with the extent of increase correlating with response to
treatment. In contrast, other studies have found a decrease in FA after 6 or 12
weeks of antipsychotic treatment in FEP patients (Q. Wang et al., 2013; Szeszko
et al., 2014) and a reduction of white matter volume (Ho et al., 2011). Interest-
ingly, in a recent study Tishler et al. (2017) investigated the association between
antipsychotic exposure duration and ICM in 93 patients with schizophrenia and
found that while medication was associated with an increase in ICM within the
first year of exposure, there was a decline thereafter.
DTI studies explicitly relating white matter integrity to treatment response status
have also procured variable results (Reis Marques et al., 2013; Garver, Holcomb &
Christensen, 2008; Luck et al., 2011; Kim et al., 2016; Szeszko et al., 2014). Two
longitudinal studies in FEP patients found that FA was reduced in the uncinate,
cingulum, and corpus callosum (Reis Marques et al., 2013) as well as superior
longitudinal fasciculi (Luck et al., 2011) at medication-free baseline in patients
who subsequently showed poor response to antipsychotic treatment. Contrary to
these findings, Kim et al. (2016) found that lower FA in similar regions was in
fact correlated with better treatment response. A further study reported increased
diffusivity, a measure of impaired white matter integrity, in treatment responders
at baseline, with subsequent repair during 28 days of antipsychotic treatment
(Garver et al., 2008).
Several groups have also studied treatment response and white matter in chronic
patient samples, reporting lower FA in treatment resistant patients compared to
healthy controls (Holleran et al., 2014) and treatment responsive patients (Mitel-
man et al., 2006; Mitelman et al., 2009). In a longitudinal design, Mitelman et al.
(2009) found that patients with a good outcome had initially higher FA compared
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to poor outcome patients, but showed a subsequent stronger decline in FA after
four years treated with antipsychotics. Similarly, white matter volume decreased
significantly in treatment responsive patients after four weeks of antipsychotic
treatment compared to an antipsychotic-free baseline in a further study, whereas
an increase was observed in treatment resistant patients (J. D. Christensen, Hol-
comb & Garver, 2004).
Taken together, the longitudinal white matter changes as a function of anti-
psychotic exposure appear to differ between patient subgroups and vary with
increasing drug exposure and illness duration. It has been argued that myelin
integrity is more heavily impacted in treatment resistant patients, such that the
limited beneficial effects of antipsychotic medication on myelination are not suffi-
cient to impact symptoms in these patients (Reis Marques et al., 2013). Altern-
atively, myelin abnormalities may be more severe in treatment responders, who
in turn show a stronger effect of medication on white matter microstructure, thus
improving neural dysconnectivity and related symptoms. A further possibility is
that while antipsychotic medication impacts white matter equally in both good
and poor responders, white matter connectivity itself is differentially associated
with symptoms in these two groups. Indeed research has found white matter integ-
rity to be correlated negatively with both negative (Knöchel et al., 2012; Wolkin
et al., 2003; Asami et al., 2014; Szeszko et al., 2014) and positive (Skelly et al.,
2008; Reis Marques et al., 2013; Cooper, Alm, Olson & Ellman, 2016) symptoms
in some studies, but positive correlations with certain positive symptom profiles
(Hubl et al., 2004) as well as no association with positive symptoms (Asami et al.,
2014) have also been reported. These inconsistent findings may be due to the het-
erogeneity of the samples included in these studies. Further research is necessary
to disentangle the relationship between antipsychotic exposure and white matter
integrity as a function of treatment response status; particularly with a focus on
the relationship between myelination and symptoms as well as cognition in these
patient subgroups.
1.6 Aims and hypotheses
The principal aim of the current work is to elucidate the neural mechanisms
underlying antipsychotic treatment response in the context of cognitive control
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and reinforcement learning. There is a dearth of functional imaging studies ex-
plicitly comparing treatment resistant and treatment responsive patients with
schizophrenia on cognitive tasks. Hence, this thesis aims to assess whether these
patient groups exhibit differential neural signatures of cognitive function which can
be related to symptoms of psychosis. In addition, myelin content will be compared
between groups as a measure of underlying structural connectivity dysfunction.
There is a need for comparisons of treatment resistant and responsive patients
with schizophrenia both at an early and chronic stage of the illness. The current
work focuses on chronic schizophrenia so as to assess neural dysfunctions at the
established stage of treatment resistance and determine how these dysfunctions
serve to perpetuate symptoms despite treatment. Both patient groups – patients
with treatment resistant schizophrenia (TRS) and non-treatment-resistant schizo-
phrenia (NTR) – will be compared to a third healthy control (HC) group on all
measures in this study.
In the first experiment, behavioural performance and neural activation will be
assessed using a verbal Stroop task. In short, participants are required to respond
to the font colour of congruent or incongruent colour words while undergoing
functional MRI scanning. Response conflict arises when the word meaning and
font colour are incongruent, and as such this constitutes a standard measure of
cognitive control. The expectation is to replicate known behavioural and neural
dysfunctions in patients with schizophrenia compared to healthy controls, with
deficits being more strongly pronounced in the TRS patient group. Given that
antipsychotic medication attenuates dopaminergic function in the striatum of all
patients, the expectation is that the key change in the treatment resistant patients
would be a greater degree of hypofrontality relative to the NTR patient group;
evident both in the between-group comparisons and more specifically as an in-
verse correlation of frontal activation with the degree of positive symptoms. This
correlation should be particularly pronounced in the TRS group. An exploratory
analysis would also demonstrate reduced functional connectivity in TRS between
frontal cortex and subcortical structures of the cognitive control network, such as
the thalamus or striatum, during response conflict in the Stroop task.
In the second experiment, behavioural performance and neural activation will be
assessed using a reinforcement learning task. Participants are required to learn
the reward contingencies of emotionally valenced faces (emotional condition) and
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neutral faces (neutral condition); whereby in the emotional condition, happy faces
are known to elicit a response bias over angry faces (Averbeck & Duchaine, 2009).
An element of cognitive control is therefore necessary to overcome the bias in
order to learn reward contingencies adequately. As such, this task allows for an
investigation of neural mechanisms underlying feedback learning as well as the
impact of bias on learning mechanisms. Neural activation correlating with reward
prediction error (RPE), known to be driven by subcortical dopamine function,
will serve as a measure of reward prediction and learning, and is expected to
be more impacted in treatment responsive patients; in contrast, the association
between bias and neural activation will index the extent to which prefrontal cog-
nitive mechanisms influence learning and is expected to be stronger in treatment
resistant patients. Thus the hypotheses for this experiment are that responsive
patients would show greater abnormalities in RPE signalling than TRS patients,
and emotional bias would differentially modulate the neural response to feedback
in TRS patients compared with both responsive patients and controls.
In the final experiment, myelin content will be assessed using multicomponent
driven equilibrium single pulse observation of T1 and T2 (mcDESPOT; Deoni
et al., 2008). This MRI technique allows for the derivation of a myelin water
fraction (MWF) map, which indicates the amount of myelin (relative to intra-
/extracellular water and cerebrospinal fluid) at each voxel in the brain. White
matter integrity has as yet not been assessed in schizophrenia using mcDESPOT.
This experiment therefore serves the purpose of testing the utility of mcDESPOT
in detecting differences in myelination between patients with schizophrenia and
healthy controls, as well as assessing whether more severe myelin-related dysfunc-
tion accounts in part for the lack of response to antipsychotic medication in TRS.
In addition, the association between myelin content and cognitive control will be
tested and mediation analyses performed so as to determine whether abnormal






Patients with a diagnosis of schizophrenia were recruited through the South Lon-
don and Maudsley (SLAM) NHS foundation trust. The “consent for contact” (c4c)
scheme within SLAM was used in order to identify eligible patients within the trust
who had previously consented to being contacted for research purposes. In line
with c4c guidelines, patients’ care coordinators were informed before contacting
patients directly. In addition, extant databases of patients who had previously
taken part in departmental research and consented to being re-contacted were
searched for eligible patients. Healthy controls were recruited via advertisements
on Gumtree.
In total, 57 patients consented to take part in the study. Of these, 22 met criteria
for treatment resistance (TRS group), and 21 met criteria for being treatment
responsive (NTR group). One patient was excluded due to non-compliance to
antipsychotic medication; two patients did not meet criteria for either patient
group; and one patient aborted the scan before data could be acquired. Twenty-
four healthy controls (HC group) consented to take part in the study. Ethical
approval was provided by the London Camberwell St Giles Research and Ethics
Committee. All participants provided informed written consent and were com-
pensated for their time and travel.
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2.1.2 Treatment resistant schizophrenia patients
The following modified Kane criteria were used for inclusion of patients into the
treatment resistant schizophrenia (TRS) group:
• at least two previous periods of treatment with antipsychotics at adequate
dosage for a period of at least four weeks without symptomatic relief
• no period of good functioning in the preceding five years
• severity score ≥ 4 on at least 2 positive symptoms items of the PANSS
The aim was to match treatment resistant and responsive patient groups as closely
as possible on key demographic and clinical variables, so as to avoid confounds
such as age, gender, illness chronicity, or medication dosage. Therefore criteria did
not specify a minimum chlorpromazine equivalent dosage for previous medication
trials in TRS patients. Instead, it was ensured that all medications had been pre-
scribed above effective therapeutic dosage (Leucht et al., 2014). In addition, we
excluded any patients currently receiving clozapine treatment due to the potential
confound that this may entail in terms of brain structure and function. This also
avoids the potential introduction of subgroups of patients resistant to clozapine
(super-resistant patients). These criteria likely lead to a more liberal inclusion of
patients into the TRS group compared to original Kane criteria; however, thor-
ough audits of medical records were conducted besides formal PANSS assessments
so as to ensure that TRS patients were experiencing persistent symptoms of at
least moderate severity despite several adequate treatment trials. Further exclu-
sion criteria were a history of neurological illness, current major physical illness,
and drug dependency over the last six months.
2.1.3 Treatment responsive schizophrenia patients
Patients in the non-treatment-resistant (NTR) group met criteria for being in
symptomatic remission (Andreasen et al., 2005), as defined by a score of 3 or less
on all items of the PANSS, and these symptoms having been stable for at least
6 months. Exclusion criteria were a history of neurological illness, current major
physical illness, and drug dependency over the last six months.
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2.1.4 Healthy controls
Healthy controls did not have a history of psychiatric illness or a first-degree rel-
ative currently or previously suffering from a psychotic illness. Further exclusion
criteria were a history of neurological illness, current major physical illness, and
drug dependency over the last six months.
2.2 Study procedures
2.2.1 General procedure
All participants were initially contacted by telephone to complete a brief screening.
This screening included questions on MRI safety, (family) psychiatric history, and
neurological history. If participants met screening criteria to be included into
the study, they were invited to attend a session at the Institute of Psychiatry,
Psychology and Neuroscience. Participants received an information sheet and
were given an opportunity to ask questions, after which signed consent was given
to take part in the research.
Participants then received instructions for the functional tasks to be completed in
the scanner (Stroop task and Faces task) and were able to practise each task until
the instructions were understood. This was followed by a behavioural assessment
session of approximately 1.5 hours duration including short breaks. If participants
were not able to complete behavioural assessments before the scanning session,
they were asked to return to the institute the following day to complete the
assessments. The MRI scan took place at the Centre for Neuroimaging Sciences
(CNS) and lasted approximately 1.6 hours.
2.2.2 Assessments
The Positive and Negative Symptom Scale (PANSS) semi-structured interview
was administered by myself and, in some cases, a further trained researcher, in
order to assess symptom severity in all patients. All participants completed pen-
and-paper questionnaires consisting of demographic information, the Aberrant
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Salience Inventory, Behavioural inhibition / Behavioural approach system scale,
Balanced Inventory of Desirable Responding, Beck Depression Inventory, and Can-
nabis Experience Questionnaire. Socio-economic status was assessed with par-
ental occupation following the National Statistics Socio-economic Classification
(NS-SEC; Rose, Pevalin & O’Reilly, 2005).
Questionnaires were followed by cognitive assessments. These included phonolo-
gical and semantic verbal fluency, letter-number-sequencing (a measure of working
memory), and the two-item subscale of the Wechsler Adult Scale of Intelligence
(WASI), consisting of the Vocabulary and Matrix Reasoning subtests (as a meas-
ure of intelligence quotient).
Sample characteristics of core demographic and clinical variables can be found in
Table 1. Remaining questionnaire and cognitive data can be found in Appendix
Table A.7.
2.2.3 MRI procedure and acquisition parameters
MRI data were acquired on a 3T GE Excite II MR scanner (GE Healthcare, USA)
with an 8-channel head coil. For the functional tasks, the task screen was viewed
via a head-mounted mirror and responses were given via a button box held in the
right hand. Throughout the scan, cardiac activity was measured with a pulse oxi-
meter attached to the participant’s finger, and respiratory activity was measured
with a pressure belt worn around the abdomen. A high-resolution structural im-
age (T1-weighted magnetization-prepared rapid gradient-echo, MP-RAGE) was
acquired, followed by T2*-weighted echo planar imaging (EPI) sequences for the
two functional tasks (Stroop task and Faces task). For the mcDESPOT protocol,
three series of scans were acquired: a spoiled-gradient recalled echo (SPGR), an
inversion recovery (IR) prepared SPGR, and a balanced steady-state free proces-
sion (bSSFP) sequence. Acquisition parameters of all scans can be found in Table
2. The MRI protocol also included a third functional task, proton magnetic res-
onance imaging (1H-MRS) of the anterior cingulate cortex, and diffusion weighted
imaging, which are not discussed further in this thesis. The duration of the full
MRI protocol was approximately 1.6 hours.
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Table 1
Means and standard deviations of demographic and clinical variables per group
HC NTR TRS
M SD M SD M SD Group statistics
X 2 (2) P
Female (%) 25.0 13.6 14.2 1.28 .527
Smokers (%) 16.7 66.7 59.1 13.43 .001
F(2) P
Age 38.4 10.0 41.3 10.4 40.8 10.9 0.52 .597
WASI 115.8 11.7 91.9 14.8 97.0 16.4 17.63 < .001
NS-SEC 3.1 1.6 3.7 1.9 3.3 1.7 0.67 .515
Onset age (years) 27.7 6.2 25.7 7.6 0.84 .365
Illness duration (years) 14.1 10.1 15.0 8.9 0.08 .781
CPZ equivalents 305.0 182.8 386.5 227.6 1.67 .204
PANSS score
Positive symptoms 10.7 2.1 20.6 3.0 153.70 < .001
Negative symptoms 13.0 5.6 19.6 4.5 18.03 < .001
General symptoms 23.6 5.1 35.1 9.1 26.11 < .001
Total score 46.9 10.3 76.7 10.5 88.39 < .001
HC = Healthy controls
NTR = non-treatment-resistant schizophrenia
TRS = Treatment resistant schizophrenia
WASI = Wechsler Abbreviated Scale of Intelligence
NS-SEC = National Statistics Socio-economic Classification
CPZ = Chlorpromazine
PANSS = Positive and Negative Syndrome Scale
2.3 Functional magnetic resonance imaging (fMRI)
2.3.1 Principals of fMRI physics
Functional magnetic resonance imaging (fMRI) is an imaging technique which
provides an indirect measure of brain activity. The utility of fMRI rests primarily
on the magnetic properties of haemoglobin molecules as a function of their oxy-
genation. Specifically, oxyhaemoglobin is diamagnetic and deoxyhaemoglobin is




Structural Stroop Faces mcDESPOT
Sequence MP-RAGE EPI EPI SPGR IR-SPGR bSSFP
Volumes 1 153 420 9 1 16
TR (ms) 7300 2000 2000 8 8 ~4
TE (ms) 3000 30 35 3.6 3.6 ~2
TI (ms) 400 450
FOV 270 211 75 220 220 220
Voxel size (mm) 1.2 3 3 1.7 2 1.7
Matrix 256×256 64×64 64×64 128×128 220×110 128×128
Flip angle 11° 75° 75° [2, 3, 4, 5,
6, 7, 9, 13,
18]°
5° [12, 16, 21,
27, 33, 40,
51, 68]°
tion level dependent (BOLD) effect (Ogawa et al., 1992). In response to neuronal
activation in the brain there is an initial small decrease in deoxyhaemoglobin in
the active region, whereupon blood flow increases in order to meet the greater
demand for oxygen. Indeed, the increase in blood flow exceeds the oxygen meta-
bolism, in effect overcompensating for the oxygen demand and resulting in an
MR signal detectable as a BOLD contrast (Buxton, 2013). The BOLD contrast is
usually measured using T2*-weighted echo planar imaging. The haemodynamic
response function (HRF) is well defined for most brain regions and can thus be
modelled in fMRI settings to estimate the evoked response to task-related stimuli.
2.3.2 Principals of fMRI processing and analysis
In event-related fMRI designs, activation in response to brief single events can
be estimated (Josephs, Turner & Friston, 1997). The assumed underlying neural
response to each event is typically modelled as a delta (or “stick”) function and
then convolved with the HRF. The scaling of the predicted response can then be
estimated within the framework of the general linear model (GLM). This operation
can thus be performed for the timecourse of each voxel in the brain in order to
identify regionally specific neural responses to task stimuli.
Before statistical inference about neural activation can be made effectively within
the GLM, fMRI data must undergo a number of preprocessing steps. The first
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preprocessing step is typically motion correction, which consists of first realigning
all acquired volumes using rigid-body transformations to account for subtle head
movement in the scanner, from which movement parameters can be estimated.
Due to the fact that head movement can cause statistical artefacts in the MR
signal, movement parameters can later be used within the GLM to partial out
these effects from the data. In addition, spatial smoothing is usually performed
by convolving the data with a Gaussian kernel with a specified full width at half
maximum (FWHM). The primary utility of spatial smoothing is an increase in
signal to noise ratio (SNR), though it comes at the cost of degraded spatial resol-
ution of the data. Temporal filtering can be performed in order to remove high or
low frequency noise, such as scanner drift or physiological noise, which in turn also
results in an increase in SNR. In order to be able to compare activation patterns
across subjects and groups, data must be normalised to a standard anatomical
space. This can be done either before or after first level (i.e. subject level) stat-
istical analyses are performed. Within the Oxford Centre for Functional MRI of
the Brain Software Library (FSL), all first level analyses are performed in subject
native space, and statistical parametric maps are then transformed into standard
space before being subjected to second level (i.e. group level) analysis.
At the first level, a GLM estimating the relative contribution of different task con-
ditions is fit to each voxel’s signal timecourse. This results in statistical parametric
maps (SPMs) containing a test statistic for each voxel, indicating how closely the
model fits each voxel’s signal. Contrast images for effects of interest are gener-
ated by weighting parameter estimates of model regressors accordingly. At the
second level, contrast images from all subjects can be subjected to mixed effects
modelling within the GLM in order to make inferences on a group level, again
resulting in SPMs containing a test statistic for each voxel. The statistical maps
can then be thresholded at a prespecified level (e.g. p < .05) in order to indicate
voxels where the signal is statistically significantly correlated with certain task
conditions. However, this mass univariate approach of estimating a GLM at each
individual voxel incurs a multiple comparison problem due to the accumulation
of the type I error rate (in this case 5%), which is further complicated by the spa-
tial dependence of proximate voxels (both due to functional similarities and the
smoothing applied during preprocessing). Gaussian random field theory (RFT)
can be applied to correct for multiple comparisons, controlling the family-wise
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error (FWE) rate and simultaneously accounting for spatial correlation of voxels
in the brain. Cluster level inference, providing information on groups of voxels
which are simultaneously active, can be made by applying a height threshold (i.e.
minimum test statistic value) and an extent threshold (i.e. minimum number of
adjacent voxels within a cluster) to each statistical map.
2.3.3 fMRI processing protocols
Functional data for both the Stroop task and the Faces task were analysed using
the general linear model as implemented in FSL FEAT, (version 5.0;Smith et al.,
2004). Functional and structural brain images were extracted from non-brain
tissue using FSL’s brain extraction tool (BET; Smith, 2002), and EPI images
were realigned using MCFLIRT to correct for effects of head motion (Jenkinson,
Bannister, Brady & Smith, 2002). A 100-s temporal high-pass filter was applied
and data was spatially smoothed using a Gaussian kernel of 5mm FWHM. The
statistical models (including motion artefact correction) used for the Stroop and
Faces tasks are described in detail in chapters 3 and 4, respectively. Due to
group differences in IQ as measured by the WASI, inclusion of WASI scores as
a covariate of no interest was considered for each task. Where task performance
significantly correlated with IQ within groups, WASI was included into fMRI
analyses to control for potential confounding effects. At the group level, significant
clusters were determined by a voxelwise z-threshold of 2.3 and a cluster significance
threshold of p=0.05 (whole-brain FWE corrected for multiple comparisons).
2.4 Multicomponent driven equilibrium single
pulse observation of T1 and T2 (mcDES-
POT)
2.4.1 Principals of mcDESPOT
Multicomponent driven equilibrium single pulse observation of T1 and T2 (mcDES-
POT) is a magnetic resonance imaging technique which makes use of the differ-
ential contributions of different tissue water compartments in the brain to the
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longitudinal (T1) and transverse (T2) relaxation signal, thereby allowing for in-
vivo volumetric quantification of myelin-associated water in the brain (Deoni et
al., 2008). Gleaning information on tissue microstructure from T1 and T2 relaxa-
tion has long been relevant both in neurology and psychiatry, however whole-brain
mapping of T1 and T2 was not always possible in clinically acceptable scan times.
K. Christensen, Grant, Schulman and Walling (1974) first proposed a new rapid
method for volumetric T1 mapping which relied on acquiring a series of spoiled
gradient recalled-echo (SPGR) images over a range of flip angles, while keeping
the relaxation time (TR) constant. This method, later termed DESPOT or DES-
POT1 (Homer & Beevers, 1985; Deoni, Rutt & Peters, 2003), provided much
faster acquisition and processing times than conventional T1 mapping techniques
and was further adapted and developed by other groups (Homer & Beevers, 1985;
H. Z. Wang, Riederer & Lee, 1987; Deoni et al., 2003; Deoni, Peters & Rutt, 2005).
It was eventually extended by Deoni et al. (2003) to achieve rapid T2 mapping
(DESPOT2) by applying the multi-flip angle technique to a steady-state free pro-
cession (SSFP) pulse sequence. The combined DESPOT1 and DESPOT2 pulse
sequences allowed for T1 and T2 mapping in under 15 minutes at high spatial
resolution.
The T1 and T2 signals describe the relaxation time of excited protons when re-
turning to longitudinal and transverse equilibrium, respectively. Tissue contrast
arises due to the different relaxation properties of tissue types in the brain. How-
ever, the DESPOT mapping technique assumes that the T1 and T2 signal in each
voxel originate from a single water compartment despite the high microstructural
complexity within each voxel. Indeed, T2 relaxation measures can typically be de-
composed into two or three components thought to correspond to separate water
compartments. For example, water trapped between the lipid bilayers of myelin
sheaths is associated with very fast T2 relaxation; intra- and extracellular water
shows intermediate T2 times; and free water in the cerebral spinal fluid (CSF) typ-
ically exhibits the slowest relaxation (Kroeker & Henkelman, 1986; Kreis, Fusch,
& Boesch, 1992; Whittall et al., 1997). This decomposition of relaxometry data
allows for volumetric quantification of microstructural tissue types by comparing
the relative contribution of each water compartment to the signal. Each voxel
can be characterised by a fraction value for each compartment, with the myelin
water fraction (MWF) constituting a widely used and histologically validated
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proxy for myelin content (Webb, Munro, Midha, & Stanisz, 2003; Laule et al.,
2006). In addition, T1 relaxation measures can be utilised to further improve
the signal decomposition using so-called 2D relaxometry (Snaar & Van As, 1992;
Does, Beaulieu, Allen, & Snyder, 1998; Does & Gore, 2002). Given the clinically
suitable acquisition time of the DESPOT protocol, Deoni et al. (2008) further
extended the technique to allow for 2D relaxometric analysis, thus introducing
mcDESPOT.
Within the mcDESPOT protocol, a whole-brain T1 map is derived from several
SPGR images acquired across a range of flip angles. Due to inevitable flip angle
errors caused by inhomogeneities within the B1 (transmit) magnetic field, an
inversion recovery (IR) SPGR image is acquired to estimate the B1 field and
correct for flip angle artefacts (Deoni, 2007). The T2 map is estimated from
several SSFP images, acquired across several flip angles and with two phase cycling
patterns (0° and 180°) to correct for (off-resonance) banding artefacts, using the
previously estimated T1 and B1 maps. Finally, a stochastic region contraction
approach is used (Deoni & Kolind, 2015) to model the SPGR and SSFP signals
with a two- or three compartment model (Deoni, Matthews, & Kolind, 2013) to
generate compartment specific T1, T2, water residence time, and fraction maps.
MWF maps contain the estimated fraction value of the myelin-associated water
at each voxel. Voxels within myelin-rich white matter regions typically show
MWF values of approximately 25-30%, whereas values within the grey matter are
expected to be below 10%.
2.4.2 mcDESPOT processing protocol
Acquisition parameters for the mcDESPOT scanning sequences can be found
in Table 2. Each subject’s scans were linearly coregistered to each other using
the highest flip angle SPGR as the reference volume with FSL FLIRT. Non-
brain parenchyma signal was then removed using FSL BET. Myelin water frac-
tion (MWF) maps were derived using in-house mcDESPOT processing software
(https://github.com/spinicist/QUIT), which includes the tools qidespot1hifi (for
simultaneous calculation of B1 and T1 maps), qidespot2fm (for simultaneous cal-
culation of off-resonance f0 and T2 maps), and qimcdespot (for calculation of
MWF maps). A three compartment model was used, assuming signal contribu-
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tions from a myelin associated species, an intra- and extracellular water compart-
ment, and a CSF species. MWF maps were then non-linearly registered to the
MNI152 2mm isotropic standard brain using FSL FNIRT and smoothed using a
Gaussian kernel at 5mm FWHM. Standardised, smoothed MWF were subjected
to statistical permutation testing using FSL RANDOMISE as described in detail
in Chapter 5.




Experiment 1: Neural mechanisms under-
lying cognitive control function in treat-
ment resistant and responsive schizophrenia
3.1 Introduction
The ability to overcome cognitive and behavioural interference is integral to effi-
cient and adaptive functioning. Cognitive control broadly represents the element
of executive function which enables one to maintain behavioural goals in the face
of interference from task-irrelevant information (Melcher & Gruber, 2009). Pre-
frontal brain regions, in particular both dorsal and rostral aspects of anterior
cingulate cortex (ACC) and lateral prefrontal cortex, are thought to play an im-
portant role in cognitive control mechanisms (Derrfuss, Brass, Neumann & von
Cramon, 2005; Di Pellegrino, Ciaramelli & Ladavas, 2007; Laird et al., 2005;
Umemoto & Holroyd, 2016; Van Veen & Carter, 2005).
Deficits in executive functions are a core characteristic of psychotic disorders, with
dysfunctions observed in cognitive control, working memory, planning, and cog-
nitive flexibility (Eisenberg & Berman, 2010; Knowles et al., 2015; Minzenberg
et al., 2009). These deficits are accompanied by altered cortical activation, most
commonly decreased activation of frontal cortical regions. A meta-analysis of ex-
ecutive function imaging studies in schizophrenia identified reduced activation in a
network of regions relevant to cognitive control, comprising dorsolateral prefrontal
cortex, ACC, and mediodorsal thalamus (Minzenberg et al., 2009). Concurrently,
hyperactivations – possibly reflecting compensatory responses – are seen in the
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ventrolateral prefrontal cortex and a midline cortical region extending from dorsal
ACC to supplementary motor area (SMA).
There is limited evidence for improvement of this cognitive dysfunction in patients
with schizophrenia with treatment, yet several lines of research suggest that the
prefrontal neural response during cognitive tasks is improved or even normalised
as a result of antipsychotic medication (Kani et al., 2017; Schneider et al., 2013;
Snitz et al., 2005). Krabbendam et al. (2009) showed that activation in inferior
frontal junction during a cognitive inhibition task increased after 6-8 weeks of anti-
psychotic treatment, and change in activation was related with positive symptom
change. However, it is unclear whether patients with schizophrenia who are resist-
ant to antipsychotic treatment are characterised by a distinct functional signature
of cognitive performance.
Treatment resistance remains a difficult problem, with up to 40% of diagnosed pa-
tients showing inadequate response to optimal antipsychotic treatment (Linden-
mayer, 2000; Mortimer et al., 2010). All antipsychotic medication acts by mod-
ulating dopamine receptors and treatment resistance occurs despite adequate D2
receptor occupancy by antipsychotic medication (Coppens et al., 1991; Wolkin
et al., 1989), indicating that alternative mechanisms to hyperdopaminergia may
be driving psychotic symptoms in the refractory patients. Treatment resistant
patients show more robust cognitive deficits compared to treatment responders
(Frydecka et al., 2016), and stronger cognitive performance is associated with
a more favourable clinical outcome (Brissos, Dias, Balanza-Martinez, Carita &
Figueira, 2011; Hofer et al., 2011). The neurophysiological underpinnings of this
remain unclear.
Schizophrenia has been repeatedly described in terms of a dysconnection syn-
drome, with frontostriatal interactions in particular postulated to be crucial in
symptom formation (Stephan et al., 2009). In this view, decreased input from
prefrontal cortex to the midbrain results in disinhibition of dopamine neurons
projecting to striatum. The resulting hyperdopaminergia leads to a state of aber-
rant salience, whereby irrelevant stimuli are imbued with special significance and
the individual develops bizarre ideas or delusions in order to explain these experi-
ences of salience (Howes & Kapur, 2009). At the same time, a failure of top-down
control signals from prefrontal areas to widespread networks may contribute to
the maintenance of psychotic symptoms as integration with bottom-up sensory
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information is disrupted (Friston & Frith, 1995).
Following from this view, one might argue that even if the striatal dopaminergic
dysfunction is alleviated with antipsychotic medication, this would not necessar-
ily suffice to reduce symptoms once they have been established if fronto-striatal
connectivity remains impaired. This model of treatment resistance would sug-
gest that functional integration is more severely impaired in treatment resistant
schizophrenia (TRS) compared to non-treatment-resistant (NTR) patients. Con-
sequently, antipsychotic treatment may effectively attenuate the striatal dopam-
inergic dysfunction, but in the absence of a normative response from prefrontal
cortex in TRS, symptoms could be perpetuated despite optimal treatment. In
contrast, NTR patients may have sufficient cognitive reserve and frontal func-
tional connectivity such that alleviating the striatal dysfunction is sufficient to
reduce symptoms adequately.
Indeed recent research has shown that frontostriatal resting-state connectivity is
more disturbed in TRS compared to non-refractory schizophrenia (T. P. White et
al., 2016). In addition, Sarpal and colleagues demonstrated that improvement of
psychosis after antipsychotic treatment is associated with increased frontostriatal
connectivity (Sarpal, Robinson et al., 2015), and that baseline connectivity may
in fact be used to predict treatment outcome in first episode psychosis (Sarpal,
Argyelan et al., 2015). However task-related functional connectivity in the con-
text of cognitive control mechanisms, which rely more heavily on fronto-thalamic
circuits (Wagner et al., 2013), has not yet been explicitly assessed in TRS.
The aim of this experiment was to investigate the neural mechanisms underly-
ing cognitive control as a function of treatment response status in patients with
a diagnosis of schizophrenia. The Stroop task, a standard paradigm for tapping
into executive control function, was used. Patients with schizophrenia have shown
both behavioural and neurofunctional deficits on this task. Improvement on the
Stroop task following antipsychotic treatment was recently linked with symptom
reductions (Krabbendam et al., 2009), but it is unclear whether treatment respon-
ders and non-responders show a differential neural profile at the chronic stage of
the illness. The hypotheses for this experiment were that:
1. Patients with schizophrenia will show slower reaction time (RT) and accur-
acy interference effects (defined as the difference between the congruent and
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incongruent conditions) compared to HC
2. Patients with schizophrenia will show reduced frontal activation during re-
sponse conflict compared to HC
3. TRS patients will show slower RT and accuracy interference effects com-
pared to HC and NTR
4. TRS patients will show reduced frontal activation during response conflict
compared to HC and NTR
5. TRS patients will show a negative association between psychotic symptom
severity and frontal activation during response conflict
6. TRS patients will show reduced connectivity between frontal and subcortical
regions of the cognitive control network compared to HC and NTR.
3.2 Methods
3.2.1 Participants
Stroop data was available for 21 patients fulfilling criteria for treatment resist-
ant schizophrenia (TRS), 21 patients with non-treatment-resistant schizophrenia
(NTR), and 23 healthy controls (HC).
3.2.2 Procedure
Subjects performed a verbal Stroop paradigm while undergoing functional mag-
netic resonance imaging. The screen was viewed via a head-mounted mirror. On
each trial, a single colour word was presented on the screen (“BLUE”, “RED”,
“GREEN”, or “YELLOW”) against a black background. The word was printed in
one of four possible font colours (blue, red, green, or yellow). Word meaning and
font colour were either congruent or incongruent, and subjects were instructed to
respond verbally to the font colour and to ignore the word meaning. In addition,
on fixation trials a central white fixation cross was presented in the centre of the
screen and no response was required. Thirty-three congruent, 33 incongruent,
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and 34 fixation trials were presented in randomised order, each with a duration
of 700ms and inter-stimulus-interval of 2300ms. Responses were recorded via a
microphone mounted inside the scanner in order to assess reaction times. Only
responses between 200 and 2700ms after stimulus presentation were recorded.
3.2.3 Behavioural data analysis
3.2.3.1 Accuracy
All trials were included in the accuracy analysis. The proportion of correct trials
was computed for each subject and compared via analysis of variance (ANOVA)
with group (HC vs. NTR vs. TRS) as between-subjects factor and condition
(congruent vs. incongruent) as within-subjects factor. Significant effects were
followed up with pairwise t-tests (Bonferroni corrected for multiple comparisons).
The Accuracy Stroop effect, defined as [Proportion correct(incongruent) – Pro-
portion correct(congruent)] was furthermore compared directly between groups
using pairwise t-tests.
3.2.3.2 Reaction time
Trials on which an incorrect response was given (2.9% of total trials) were removed
from further analysis. Mean reaction times (RTs) were analysed via ANOVA with
group (HC vs. NTR vs. TRS) as between-subjects factor and condition (congru-
ent vs. incongruent) as within-subjects factor. Significant effects were followed
up with pairwise t-tests (Bonferroni corrected for multiple comparisons). The
RT Stroop effect, defined as [RT(incongruent) – RT(congruent)] was furthermore
compared directly between groups using pairwise t-tests.
3.2.4 Neuroimaging data analysis
3.2.4.1 First level analysis
For the first level analysis, regressors representing onsets of stimulus presenta-
tion for incongruent trials and congruent trials were included into the model.
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Each regressor was modelled as a delta function and convolved with a canon-
ical haemodynamic response function. Potentially exacerbated motion artefacts
were anticipated due to the verbal nature of responses given during the task;
thus comprehensive motion regression was performed. Both standard and exten-
ded motion parameters were included as nuisance regressors. Standard motion
parameters include 3 rotational and 3 translational movement parameters, and
extended parameters consist of the derivatives of the standard parameters, as
well as the squares of the standard parameters and their derivatives. In addition,
to correct for physiological noise, cardiac and respiratory signals were modelled
using FSL’s Physiological Noise Modelling (PNM) as described in Brooks et al.
(2008). Cardiac and respiratory regressors (principal frequency and first three
harmonics) as well as their interactions were created, resulting in a total of 32
regressors which were treated as voxelwise confounds in FEAT.
For each subject, contrasts of interest included the Stroop contrast (defined as
[Incongruent – Congruent]) and the Incongruent contrast. The Stroop contrast
is typically used to capture pure interference effects by subtracting the congru-
ent condition, which does not entail a response conflict, from the incongruent
interference condition. However, given the randomised order of trial conditions,
it is likely that the congruent condition may also contain an element of cognitive
control, which may thus be subtracted out in the Stroop contrast. The simple
Incongruent condition contrast was therefore also assessed separately.
3.2.4.2 Second level analysis
Mean activation differences The first level contrast images for the Stroop
and Incongruent contrasts, respectively, were subjected to separate mixed effects
group level analyses (FLAME1) modelling the effect of group. In a first analysis,
contrast images of NTR and TRS patients were pooled into one patient group so as
to assess mean activation differences between HC and patients. Due to significant
differences between groups on the WASI IQ scores and significant correlations
between WASI and the RT Stroop effect both in NTR (R=-0.66, p= .001) and
TRS (R=-0.68, p< .001), WASI was included as a covariate of no interest. In a
second analysis, mean activation differences between NTR and TRS patients were
analysed. Chlorpromazine (CPZ) equivalent medication dosage was included as a
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covariate of no interest. Where group differences were not significant on a whole-
brain level, region of interest (ROI) analyses were performed. Functional ROIs
were defined as activation clusters which were significant across all groups (i.e. in
the F contrast [1 1] across both groups). Mean parameter estimates were extracted
from these clusters for each subject and then specifically compared between groups
using one-way ANOVA.
Correlations with psychotic symptoms In order to test for differential cor-
relations between symptoms and brain activation in the two patient groups, fur-
ther analyses of the Incongruent contrast were conducted modelling the effect of
group (NTR vs. TRS) and PANSS positive symptom score. A group × symptom
score interaction term tested specifically whether the two groups showed differen-
tial correlations between neural activation and symptoms. An identical analysis
was conducted with PANSS negative symptom scores. CPZ equivalent dosage
was included as a covariate of no interest.
Functional connectivity analysis Finally, a psychophysiological interaction
(PPI) analysis was conducted to assess differences in functional connectivity dur-
ing the Incongruent condition between the three groups. A cluster in the ACC
identified in the previously described symptoms analysis was used as a seed region.
An ROI mask consisting of bilateral striatum and thalamus (anatomically defined
from the probabilistic Harvard Oxford Subcortical Structural Atlas thresholded
at 30%, see Appendix Figure A.1) was used to directly assess connectivity of the




The ANOVA on proportion of correct trials revealed a significant main effect of
group, F(2,62)= 5.18, p= .008, a significant main effect of condition, F(1,62)= 36.71,
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p< .001, as well as a significant group × condition interaction, F(2,62)= 4.58,
p= .014 (see Figure 1). Post-hoc comparisons showed that groups performed sim-
ilarly on congruent trials, all ps> .05. In contrast, on incongruent trials, HC had
a higher mean proportion of correct trials compared to NTR, p= .03, and TRS,
p= .005 (Bonferroni corrected).
Pairwise comparisons revealed that both TRS (M=6.6%; SD=8.4%) and NTR
(M =7.5%; SD=7.9%) showed a greater accuracy Stroop effect than HC (M =1.7%;
SD=3.4%), all ps< .05 (Bonferroni corrected), with no difference between the two
patient groups, p= .999.
Figure 1. Mean proportion correct
by group and condition. Error bars
represent the standard error of the
mean.
Figure 2. Mean reaction time in ms
by group and condition. Error bars
represent the standard error of the
mean.
3.3.1.2 Reaction time
For the RT data, there was a significant main effect of group, F(2,62)= 3.35,
p= .042, a significant main effect of condition, F(1,62)= 109.00, p< .001, as well
as a significant group × condition interaction, F(2,62)= 5.23, p= .008 (see Figure
2). Groups did not differ significantly on congruent trials, whereas on incon-
gruent trials HC responded significantly faster compared to NTR, p= .019, and
marginally compared to TRS, p= .060 (Bonferroni corrected).
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Pairwise comparisons revealed that both TRS (M =186.66 ms; SD=128.26 ms)
and NTR (M =169.78 ms ; SD=129.95 ms) showed a greater RT Stroop effect
than HC (M =85.14 ms; SD=71.87), all ps< .05 (Bonferroni corrected), with no
difference between the two patient groups, p= .627.
3.3.2 Neuroimaging data
3.3.2.1 Mean activation differences
HC vs. Patients Across both groups, subjects showed Stroop-related BOLD
signal in a midline section extending from paracingulate gyrus to supplementary
motor area (SMA) as well as bilateral precentral gyri (see Appendix Table A.1).
There was no whole-brain group effect at a voxelwise level. However, functional
ROI analyses on the three significant activation clusters revealed that patients
with schizophrenia showed significantly increased activation compared to HC in
the cluster extending from dorsal ACC to SMA (Figure 3).
Across groups on Incongruent trials, subjects showed extensive activation of areas
classically associated with the Stroop task, including bilateral superior frontal
gyri, two large clusters extending from bilateral precentral gyri to the superior
temporal lobes, as well as bilateral precuneous cortex and lateral occipital lobes
(see Appendix Table A.2). Whole-brain group differences were found in two signi-
ficant clusters (Table 3), with patients showing attenuated activation compared to
HC in left superior parietal cortex extending to lateral occipital cortex as well as in
the right insula extending anteriorly to OFC and posteriorly to the hippocampus
(Figure 4).
NTR vs. TRS There were no significant mean activation differences between
the NTR and TRS groups for the Stroop contrast or the Incongruent contrast
either at a voxelwise level or within functional ROIs.
3.3.2.2 Correlations with psychotic symptoms
A further analysis in patients only with PANSS positive symptoms as covariate
and controlling for medication dosage showed a differential relationship between
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Table 3
Significant clusters for the effect of group (Healthy controls vs. patients) on the
Incongruent contrast
Region Side k z MNI
Insula R 973 4.31 44 8 -6
Hippocampus R 34 -30 -6
Hippocampus R 36 -30 -6
Hippocampus R 34 -38 4
Orbitofrontal cortex R 22 8 -14
Hippocampus R 16 -16 -16
Superior parietal cortex L 2474 3.97 -6 -60 60
Superior parietal cortex L -28 -34 52
Precuneous cortex L -12 -50 56
Superior parietal cortex R 14 -48 58
Postcentral gyrus L -16 -48 58
Postcentral gyrus L -14 -48 62
positive symptoms and BOLD response in rostral ACC in NTR compared to TRS
(Table 4; Figure 5A). As can be seen in Figure 5B, activation in rostral ACC was
positively correlated with PANSS positive score in NTR (R=0.58, p= .007), but
negatively correlated in TRS (R=-0.44, p= .048).
Table 4
Significant cluster for the positive symptom × group effect on the Incongruent
contrast
Region Side k z MNI
Anterior cingulate cortex R 1000 3.46 4 36 6
Anterior cingulate cortex R 10 40 4
Paracingulate gyrus R 14 48 2
Paracingulate gyrus R -14 42 -4
Paracingulate gyrus R 12 46 -4
Anterior cingulate cortex R -2 36 6
In addition, exploratory correlation analyses of rostral ACC activation and task
performance were conducted (Figure 5C). In the TRS group, deactivation of ACC
was associated with slower mean RTs in the incongruent condition (R=-0.56,
p= .008). This correlation differed significantly from that in both NTR (R=-
0.02, p= .929) and HC (R= -0.05, p= .811), as established with Fisher’s R to Z
transform (both z >2.1, ps< .05).
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Figure 3. Activation for Stroop contrast across groups (A) and mean
parameter estimates (PEs) for supplementary motor area region of interest in
healthy controls (HC) and patients (B). Activation maps reflect z-values
thresholded at 2.3, corrected p < .05.
The equivalent analysis using PANSS negative symptom score as covariate did
not yield any significant group × symptom effect.
3.3.2.3 Functional connectivity analysis
Finally, a functional connectivity analysis controlling for WASI scores was run
using the reported rostral ACC cluster shown in Figure 5A as seed region and a
subcortical mask including bilateral thalamus and striatum as ROI. Across the
three groups significant connectivity was found with bilateral dorsal thalamus
(Table 5; Figure 6A). Mean connectivity parameter estimates for each group can
be seen in Figure 6B. Pairwise comparisons on mean parameter estimates re-
vealed a trend towards reduced connectivity between ACC and dorsal thalamus
in TRS compared to HC, p< .063 (uncorrected), Cohen’s d =0.63. There was no
significant difference between NTR and HC, or NTR and TRS.
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Figure 4. Activation for Incongruent contrast across groups (A) and
whole-brain significant clusters of group differences (B). Activation maps reflect
z-values thresholded at 2.3, corrected p < .05.
3.4 Discussion
The aim of this experiment was to compare cognitive control mechanisms in
patients with schizophrenia who were either treatment resistant (TRS) or non-
treatment-resistant (NTR) and healthy controls (HC). The focus lay in identi-
fying whether more pronounced cognitive control deficits could account for per-
sistence of psychosis despite optimal treatment in TRS. On a behavioural level,
both patient groups showed similarly impaired performance, with increased re-
action time interference effects compared to healthy controls and no significant
between-patient subgroup differences. In a similar vein, there were no significant
differences in overall BOLD response between the two patient groups. Rather, pa-
tients showed increased activation of dorsal ACC extending to SMA compared to
HC on the interference Stroop contrast, consistent with a compensatory response
observed in earlier studies (Johnson et al., 2006; Minzenberg et al., 2009; Tan
et al., 2006). On incongruent trials, patients showed attenuated activation com-
pared to HC in superior parietal cortex and left insula extending to orbitofrontal
cortex, regions previously implicated in cognitive control deficits in schizophrenia
(Minzenberg et al., 2009). In sum, overall behaviour and neural activation in this
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Figure 5. Anterior cingulate cortex (ACC) region showing significant group ×
positive symptom score interaction (A); correlation between mean parameter estimate
in ACC and positive symptom score by group (B); and correlation between mean
parameter estimates (PEs) in ACC and mean reaction time on incongruent trials by
group (C). Activation maps reflect z-values thresholded at 2.3, corrected p < .05.
particular task do not adequately differentiate between the two patient groups.
A further analysis investigated how both positive and negative symptoms mod-
ulate neural activation on this task in the two patient subgroups. There was no
significant effect for negative symptoms. Intriguingly, there was a differential asso-
ciation between BOLD response in rostral ACC and positive symptom severity in
the two patient subgroups. While higher positive symptoms were associated with
a higher BOLD response in NTR, increased positive symptoms were associated
with ACC deactivation in TRS. This suggests a differential role for ACC func-
tioning in these two groups during cognitive interference: the most unwell TRS
patients showed the strongest ACC deactivation, which in turn predicted slower
response times on the task. In contrast, the NTR group demonstrated the greatest
deactivation in the least symptomatic patients, and this was unrelated to beha-
viour. Significant dysfunction of the ACC in schizophrenia has been observed in
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Table 5
Significant cluster for the functional connectivity analysis with anterior cingulate
seed
Region Side k z MNI
Thalamus R 763 3.95 -6 0 4
Thalamus R 4 -26 4
Caudate L -6 6 4
Thalamus R 4 -20 14
Thalamus R 4 -4 4
Thalamus L -2 -26 4
both structural and functional imaging (Fornito, Yücel, Dean, Wood & Pantelis,
2009; McGuire et al., 1998; Radua et al., 2012), and is associated with executive
dysfunction in the illness (Glahn et al., 2005; Kerns et al., 2005; Szeszko et al.,
2000). Snitz et al. (2005) showed that ACC functioning is improved after four
weeks of antipsychotic treatment. These findings suggest that this may not be the
case in the most severe cases of TRS. In light of the involvement of glutamater-
gic neurotransmission in cognitive control processes (Falkenberg, Westerhausen,
Specht & Hugdahl, 2012; Lorenz et al., 2015; van Wageningen, Jorgensen, Specht
& Hugdahl, 2009), as well as suggestions that prefrontal glutamate may differ-
entially modulate cognitive control processes in patients with schizophrenia, it is
possible that aberrant ACC function and connectivity in the more symptomatic
TRS patients may be related to altered ACC glutamate levels previously reported
in TRS (Demjaha et al., 2014; Egerton et al., 2012; Mouchlianitis et al., 2015).
Previous neuroimaging studies of the Stroop task have reported involvement of
a fronto-striato-thalamic network (Bari & Robbins, 2013; Chambers, Garavan &
Bellgrove, 2009) that regulates inhibitory control. The PPI analysis identified
a region in the dorsal thalamus which showed significant functional connectiv-
ity with ACC on incongruent trials, in line with these reports. The strength of
connectivity was indistinguishable in the HC and NTR groups, but there was a
tendency towards reduced connectivity in TRS. This reduction was only margin-
ally significant and must thus be interpreted with caution; however the moderate
effect size suggests that the effect may be more evident in a larger sample with
reduced variability.
Taken together, the results indicate that despite similar overall activation pat-
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Figure 6. Dorsal thalamus region showing significant functional connectivity
with anterior cingulate seed (A); and mean parameter estimates (PEs) within
this region by group (B). Activation maps reflect z-values thresholded at 2.3,
corrected p < .05.
terns on this version of the Stroop task, patients with treatment resistant schizo-
phrenia are differentiated by a unique association of ACC function with symptom
severity, accounting in part for the observed behavioural deficits. In addition,
though only a preliminary finding which did not survive stringent corrections, the
trend towards weakened connectivity of this region with dorsal thalamus, a key
region in the cognitive control network, is in line with a lack of functional frontal-
midbrain integration which may play a role in perpetuating symptoms despite
optimal treatment. While there were no frontal activation differences between the
two patient subgroups, the relationship of ACC activation and positive symptoms
differed significantly. The positive relationship in NTR and negative relation-
ship in TRS is best conceptualised as an inverse U-shaped curve across the range
of positive symptoms: cognitive control as reflected in ACC activation initially
increases as symptoms increase, but as symptoms become more severe, the inhib-
itory process fails. The inverted U-shape is analogous to that seen in frontal and
70
parietal activation as cognitive load increases during working memory tasks (Cal-
licott et al., 1999; Linden, 2007). One speculation might be that a compensatory
neural response is effective in maintaining behavioural performance up to a certain
threshold, upon which increased task demands are met with an inversion of the
neural response and performance deteriorates. The findings of this experiment
support the notion that alleviation of striatal dysfunction by antipsychotics is not




Experiment 2: Neural mechanisms under-
lying reinforcement learning in treatment
resistant and responsive schizophrenia
4.1 Introduction
Schizophrenia has frequently been studied within a framework of reinforcement
learning given the involvement of dopamine function in reward prediction (Deserno
et al., 2016). Reinforcement learning is driven by midbrain dopamine neurons
encoding violations of expected reward outcomes (Schultz, 1998), known as reward
prediction error (RPE) signals. RPE signalling in the striatum has been shown
to be reduced in schizophrenia patients (Schlagenhauf et al., 2014; G. Murray et
al., 2008; Waltz et al., 2009), a finding attributed to “drowning” of these phasic
signals due to elevated presynaptic dopamine. Dysfunctional RPE signalling has
been related to both positive (Corlett et al., 2007; Gradin et al., 2011) and negative
(Waltz et al., 2009; Moran, Owen, Crookes, Al-Uzri & Reveley, 2008) symptoms
and is intimately linked with the aberrant salience hypothesis of schizophrenia.
According to this account, excessive subcortical dopamine activity observed in
patients (Howes & Kapur, 2009) would lead to dopamine neurons firing out of
context, leading to a perplexing state where environmental stimuli acquire value
that cannot be logically explained by the individual without developing unusual
ideas, or delusions (Howes & Kapur, 2009; Kapur, 2003; Kapur et al., 2005).
The question of whether a common dopaminergic abnormality underlies both
treatment responsive and treatment resistant schizophrenia (TRS) remains cru-
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cial. Plausibly, an alternative aberrant mechanism may give rise to symptoms
in TRS (Demjaha et al., 2012) and drive reinforcement learning deficits in these
patients. Importantly, reinforcement learning relies not only on striatal dopamine
function, but also on complex cortico-subcortical interactions regulating related
processes such as cognitive control, goal maintenance and planning, as well as
action value and effort computations (Barch & Dowd, 2010; Frank, Loughry &
O’Reilly, 2001b; Frank & Claus, 2006). As bottom-up learning signals are util-
ized to update a model of the surrounding environment, it is necessary to exert
top-down cognitive control – particularly in the presence of persistent cognitive
or behavioral bias – in order to optimise task focused learning. As such, it is
possible that even with intact RPE signalling, a lack of cognitive control modu-
lating learning processes could lead to a disruption of reinforcement learning. In
particular, while cognitive biases occur in all individuals, the manner in which
these interact with subcortical learning processes may be crucial with respect to
TRS.
There is a distinct lack of studies investigating the cognitive and neural mech-
anisms underlying these processes directly in treatment resistant and treatment
responsive individuals with schizophrenia. In this experiment, these groups are
compared using functional magnetic resonance imaging (fMRI) while investigating
1) neural correlates of RPEs during wins and losses and 2) the influence of cog-
nitive bias on these learning signals. A probabilistic reinforcement learning task
was used in which subjects learned reward contingencies of faces with varying
emotional expressions (Averbeck & Duchaine, 2009). Both healthy controls and
patients with schizophrenia have been shown to exhibit an emotional bias towards
happy faces on this task, evident as more frequent choices for happy faces (versus
angry faces) even when the reward feedback is equivalent (Evans et al., 2011).
The task, therefore, sets up a conflict between reward processing and emotions,
as optimal learning would ignore the emotional expressions.
In the current experiment, RPE signalling was examined separately for wins and
losses on this task both because dissociable systems have been suggested for pre-
diction error signalling of rewards and losses (Yacubian et al., 2006; Garrison
et al., 2013) and due to evidence that reward and loss processing may be dif-
ferentially impacted in schizophrenia (Chang, Waltz, Gold, Chan & Chen, 2016;
Reinen et al., 2016; Waltz et al., 2007; Waltz et al., 2011). In addition it was
73
anticipated that this would more closely reflect variabilities in prediction errors
rather than effects of outcome itself. Based on the theory that treatment respons-
ive schizophrenia, but not TRS, is characterised by an abnormal dopaminergic
signature, this experiment tested the hypotheses that:
1. All groups will show an emotional bias towards the happy face
2. Patients with schizophrenia will show impaired learning in both the emo-
tional and neutral condition compared to HC
3. RPE signalling will be attenuated specifically in NTR patients compared to
HC and TRS
4. TRS will show a greater impact of bias on neural response to feedback in
the emotional condition compared to NTR patients and HC.
4.2 Methods
4.2.1 Participants
Faces task data was available for 21 patients fulfilling criteria for treatment resist-
ant schizophrenia (TRS), 21 patients with non-treatment-resistant schizophrenia
(NTR), and 24 healthy controls (HC).
4.2.2 Procedure
Subjects underwent a reward learning paradigm which consisted of choosing between
two simultaneously presented faces, learning which of the faces was associated
with a higher reward probability over a series of iterative trials. The subjects
were asked to maximise the reward achieved in the task. The task consisted of
four blocks of 30 trials each. Blocks 1 and 3 were emotional blocks, and blocks
2 and 4 were neutral blocks. In emotional blocks, the two faces had the same
identity but one showed a happy expression while the other showed an angry ex-
pression. In neutral blocks both faces wore neutral expressions but consisted of
two separate identities. In each block one face was associated with a 60% reward
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probability and the other with a 40% reward probability. The order in which
identities and expressions were associated with the higher reward probability was
counterbalanced across subjects. A schematic of a trial sequence is shown in
Figure 7.
Figure 7. Schematic of task sequence (neutral block). Background and text
colours are inverted. The chosen face was highlighted with a yellow box
surrounding it.
Each trial began with a period of 1000 ms during which a white central fixation
cross was presented against a dark background. This was followed by two faces
being presented to the right and left of the fixation cross for 4500 ms. Within
this time window subjects were required to select one of the faces by pressing the
corresponding button with their right hand. The selected face was highlighted by
a yellow square surrounding it. Feedback was then presented on the screen for a
duration of 1500 ms. If the correct face was chosen, the words “You win 10 pence.
Total is X pence” were presented, with X representing the running total for the
task. If the incorrect face was chosen, the words “You lose” were presented. The
total did not change after an incorrect choice.
4.2.3 Behavioural data analysis
The behavioural data was modelled using a “double update” reinforcement learn-
ing (RL) model (Schlagenhauf et al., 2014). Choice probability for choosing option
1 on trial t was computed on each trial using the softmax function
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P1(t) = exp(β×Q1(t))exp(β×Q1(t))+exp(β×Q2(t))
where the inverse temperature β determines the randomness of the subject’s
choice, and Q1(t) denotes the action value, or expected reward, for choice 1 on
trial t. The action value for the chosen option is updated on a trial-by-trial basis
using the reward prediction error, defined as the difference between the expected
reward Q and obtained reward R on trial t, scaled by the learning rate parameter
α.
Q1(t+ 1) = Q1(t) + α(R(t)−Q1(t))
The action value for the unchosen option 2 was additionally updated on each trial,
using the inverse reward value R (1 if the chosen option lost, and 0 if the chosen
option won) and identical learning rate parameter:
Q2(t+ 1) = Q2(t) + α(R(t)−Q2(t))
This model reflects the symmetry of choice outcomes, whereby feedback associated
with a chosen option is also informative of the unchosen option (e.g., if stimulus
1 lost, stimulus 2 would have won).
The two free parameters β and α were estimated for each group separately by min-
imizing the negative log likelihood of the observed data pooled across all subjects
within the group. Action values Q1 and Q2 were both initialised at 0. A hundred
optimisations were performed for each group so as to avoid local minima, with
starting values for α randomly drawn from a uniform distribution between 0 and
1 and starting values for β randomly drawn from a uniform distribution between
0 and 10.
Choices on each trial were defined as ideal if the action value (computed by the
model) of the chosen option was greater than that of the unchosen option. Sub-
jects’ proportions of ideal choices were compared between groups (HC vs. NTR
vs. TRS) and conditions (emotional vs. neutral) using mixed effects ANOVA.
Emotional bias was defined as the difference between the proportion of choices
for the happy face when the angry face would have been an ideal choice, and
proportion of choices for the angry face when the happy face would have been
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the ideal choice. Emotional bias was compared between groups using one-way
ANOVA.
All behavioural analyses were conducted in R (R Core team, 2013).
4.2.4 Imaging data analysis
4.2.4.1 First level analysis
For the first level analysis, the phases of the task (face presentation, choice, win
outcome, and loss outcome) were modelled separately for emotional and neutral
trials, resulting in eight unmodulated regressors. Additional parametric regressors
were included for the win outcome and loss outcome phases, using RPE as modu-
lator, again separately for emotional and neutral trials, resulting in four additional
parametrically modulated regressors.
Each regressor was modelled with a delta function of zero duration and convolved
with a canonical hemodynamic response function and its temporal derivative.
Six standard motion parameters as well as a motion artefact confound matrix,
which identified motion-corrupted volumes, were added as regressors of no in-
terest. Volumes detected as corrupted were calculated by DVARS (Power, Barnes,
Snyder, Schlaggar & Petersen, 2012) as implemented by FSLMotion Outliers. The
percentage of corrupted volumes did not differ between groups, F(2,60)= 0.166,
p> .848 (HC: N =24; M =0.4%, SD=0.2%; NTR: N =21; M =0.4%, SD=0.2%;
TRS: N =18; M =0.4%, SD=0.3%).
Contrasts of interest were created for RPE regressors, either averaging across con-
ditions or contrasting emotional and neutral condition, resulting in the following
contrasts of interest: 1) win RPE; 2) loss RPE; 3) win RPE [emotional > neutral];
4) loss RPE [emotional > neutral].
4.2.4.2 Second level analysis
Mean activation differences At the group level, contrasts were submitted to
separate mixed effects analyses (FLAME1), modelling the effect of group (HC,
NTR, or TRS) on BOLD signal. Whole-brain activation differences between
groups were tested for win RPE and loss RPE. In order to detect subcortical
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RPE activation an ROI analysis was conducted using a binary subcortical mask
consisting of the bilateral striatum and thalamus (anatomically defined from the
probabilistic Harvard Oxford Subcortical Structural Atlas thresholded at 30%, see
Appendix Figure A.1).
Correlations with emotional bias In order to assess the differential effect of
emotional bias on RPE-related signal, analyses of the win RPE [emotional>neutral]
and loss RPE [emotional>neutral] contrasts included emotional bias as a covari-
ate, and group × bias interaction effects were assessed.
4.3 Results
4.3.1 Behavioural results
The proportion of ideal choices differed significantly between the three groups,
F(2,63)= 3.69, p= .031, with HC (M =0.63, SD =0.13) making significantly
more ideal choices compared to NTR patients (M = 0.55, SD = 0.13), p = .006,
as well as compared to TRS patients (M = 0.57, SD = 0.11), p = .048. There
was no significant difference between NTR and TRS patients, p > .05 (post-
hoc t-tests Bonferroni corrected for all three pairwise comparisons). There was
no significant main effect of (emotional vs. neutral) condition, and no group ×
condition interaction, ps> .05.
There was a significant positive emotional bias across subjects (M =0.8, SD=0.17,
p< .001) indicating a preference for choosing the happy over the angry face. Emo-
tional bias did not differ significantly between groups, p> .05 (HC: M =0.06,
SD=0.13; NTR: M =0.13, SD=0.22; TRS: M =0.04, SD=0.16).
4.3.2 Neuroimaging results
4.3.2.1 RPE signalling for wins and losses
Figure 8A shows the pattern of RPE-related activation in response to win out-
comes in HC, who showed a significant signal in bilateral dorsolateral prefrontal
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cortices, parietal cortices and occipital cortex extending to cerebellum (see Ap-
pendix Table A.3). TRS patients showed a similar activation pattern (Figure 8B;
see Appendix TableA.4). In contrast, NTR patients showed no supra-threshold
RPE-related activation. Group comparisons showed that NTR patients had sig-
nificantly reduced RPE-related activation in precentral gyrus compared to TRS,
in angular gyrus compared to HC, as well as in cerebellum compared to both HC
and TRS (Table 6; Figure 9). The subcortical ROI analysis revealed a significant
effect of group (p< .05 uncorrected), with NTR patients showing reduced RPE-
related activation in bilateral thalamus and caudate head compared to both HC
and TRS (Figure 10).
Table 6
Significant clusters for the effect of group on reward prediction error related
activation during wins
Region Side k z MNI
HC > NTR
Angular gyrus R 690 3.41 50 -66 32
Middle temporal gyrus R 42 -48 4
Angular gyrus R 46 -54 18
Angular gyrus R 34 -50 38
Angular gyrus R 42 -54 18
Cerebellum R 1736 3.69 0 -54 -20
Cerebellum R 2 -74 -14
Occipital fusiform cortex R 16 -78 -12
Cerebellum L -24 -80 -26
Cerebellum R 16 -64 -18
Occipital pole R 12 -90 4
TRS > NTR
Precentral gyrus R 991 2.66 64 2 26
Precentral gyrus R 54 -4 28
Supramarginal gyrus R 62 -28 22
Postcentral gyrus R 62 -6 36
Precentral gyrus R 48 -6 30
Precentral gyrus R 58 0 12
Cerebellum R 19885 4 -54 -20
Cerebellum L -18 -38 -24
Cerebellum R 16 -46 -22
Cerebellum L -10 -44 -22
Cerebellum R 12 -46 -22
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Figure 8. Neural response correlating with reward prediction error (RPE)
during wins in healthy controls (A) and treatment resistant schizophrenia (B) as
well as during losses in healthy controls (C) and treatment resistant
schizophrenia (D). Activation maps reflect z-values thresholded at 2.3, corrected
p < .05.
Loss-related RPE response was observed in a widespread network in both HC and
TRS (see Appendix Tables A.5 and A.6), similar to that during win outcomes
(Figures 8C and 8D). Due to the negative sign of loss-related RPE, this signal
reflects a negative RPE signal, with greater prediction errors resulting in greater
deactivation in these areas. The NTR group showed no significant supra-threshold
RPE related signal, but there were no significant group differences at whole-
brain level. The subcortical ROI analysis revealed reduced RPE-related signal in
bilateral pallidum and caudate in NTR compared to HC (p< .05 uncorrected) and
no significant difference between TRS and either of the other two groups (Figure
10B).
4.3.2.2 Emotional bias × group interaction on RPE signal
During the emotional (versus neutral) loss trials, the whole-brain analysis showed
a significant group × emotional bias interaction on RPE signal in bilateral thal-
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Figure 9. Group differences in neural reward prediction error related activation
during wins. Activation maps reflect z-values thresholded at 2.3, corrected p <
.05.
amus and caudate nucleus, indicating a differential correlation in TRS and NTR
patients (Table 7; Figure 11). In TRS patients, a stronger emotional bias was as-
sociated with increased RPE signal in this region (R=0.58, p= .006). In contrast,
in NTR patients, the opposite was the case (R=-0.56, p= .008). This negative
correlation in NTR was no longer significant after excluding one outlier, however
the difference between correlation coefficients in the two groups remained signi-
ficant (Fisher’s R to Z =2.69, two-tailed p= .007). Interestingly, RPE signal in
this region was significantly correlated with delusion severity in TRS patients,
with stronger RPE signalling associated with more severe symptoms of delusions
(R=0.48, p= .027).
The equivalent analysis on emotional (versus neutral) win trials did not yield a
significant group × emotional bias interaction.
Table 7
Significant cluster for the emotional bias × group effect on reward prediction
error related activation during emotional (vs. neutral) loss trials
Region Side k z MNI
Thalamus L 593 3.33 -6 -10 14
Caudate L -18 -4 16
Caudate L -16 0 16
Thalamus L -12 -10 16
Caudate L -20 -22 18
Thalamus L 0 -18 16
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Figure 10. Subcortical region of interest analysis (p < .05, uncorrected) of
group differences in reward prediction error signal during wins (A) and losses
(B). Bar plots represent the mean parameter estimate across the significant
voxels.
4.3.2.3 Exploratory correlation analyses
For each of the significant clusters showing group differences in RPE-related ac-
tivation either during wins or losses, exploratory analyses of correlations between
BOLD signal and WASI scores as well as CPZ equivalent medication dosages
were conducted within each group. No correlation was significant, all ps> .05
(uncorrected for multiple comparisons).
4.4 Discussion
In this experiment, a probabilistic reward learning task was used to assess dif-
ferences in neural mechanisms underlying reinforcement learning in patients with
schizophrenia who were either treatment resistant (TRS) or treatment responsive
(NTR), relative to a healthy control (HC) group. The experiment tested the hypo-
thesis that NTR patients would show abnormal prediction error related activation
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Figure 11. Group × emotional bias interaction in prediction error signal during
losses. Activation maps reflect z-values thresholded at 2.3, corrected p < .05.
compared to both HC and TRS, based on the theory that the responsive patient
group is characterised by a greater disruption of dopaminergic signalling. In addi-
tion, the hypothesis was tested that underlying cognitive bias would differentially
modulate learning processes in the two patient groups.
The results revealed that HC and TRS patients showed similar patterns of predic-
tion error signalling both during wins and losses. RPE activation was evident in a
widespread network in these groups, consistent with the notion that reward pro-
cessing is almost ubiquitous in the brain (Vickery, Chun & Lee, 2011). In contrast,
NTR patients did not exhibit the same activation pattern and showed significant
reductions in parietal, occipital and cerebellar regions during wins. Subcortically,
an ROI analysis showed hypoactivation in the striatum and thalamus specifically
in NTR patients. These findings imply that putatively dopamine-driven mech-
anisms underlying reinforcement learning in response to reward feedback are dis-
rupted in NTR, while remaining relatively intact in TRS. The data are consistent
with the notion that TRS patients do not respond to dopaminergic antipsychotic
medication because a dopaminergic abnormality is not the primary cause of symp-
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toms in this subgroup (Demjaha et al., 2012).
Interestingly, groups did not differ in terms of their bias towards choosing the
happy face over the angry face on emotional trials. However, there was a signi-
ficant difference between TRS and NTR patients in how this bias was associated
with RPE signal in the thalamus and caudate during loss processing. In NTR
patients, a strong emotional bias was associated with further attenuation of the
RPE signal. By comparison, emotional bias in TRS was associated with an in-
creased RPE signal. In turn, RPE signal in this region was positively related to
delusional symptom severity specifically in the TRS group. This is surprising as
RPE signalling has previously been reported to be negatively linked with symp-
tom severity in schizophrenia (Corlett et al., 2007; Gradin et al., 2011); in line
with the view that hyperdopaminergia – reflected in reduced RPE signal signalling
– drives psychosis. The findings suggest that this relationship may be inverted in
TRS patients in the thalamus and caudate. Increased RPE signalling specifically
on loss trials may reflect less accurate predictions, resulting in greater prediction
errors when the outcome is negative. As such, a strong emotional bias in TRS
may lead to worse predictions about outcomes but an intact subcortical response
to prediction error, which in turn is not adequately utilized to update predictions.
In contrast, in NTR the prediction error response itself seems to be impaired, an
effect which is further augmented in the presence of cognitive bias.
It is worth noting that the differences in striatal RPE activation between groups
were apparent only at a liberal statistical threshold uncorrected for multiple com-
parisons. However, the consistent pattern of hypoactivation in NTR patients
across the network lends support to this finding as a true positive. Subcortical
dysfunctions in reward processing in NTR may be particularly hard to detect given
that these may be ameliorated in chronic patients after antipsychotic medication
(Culbreth et al., 2016).
These data support a model of TRS whereby the central dysfunction lies not in the
subcortical dopamine system itself, but in the cognitive mechanisms interacting
with this system. The striatum and cortex are interconnected by multiple partially
overlapping circuits subserving learning and flexible cognition (Kehagia, Murray
& Robbins, 2010). The ability to maintain behavioural goals in the presence of
interference, uncertainty, or bias – broadly the definition of cognitive control –
is an integral aspect of feedback learning. A breakdown of this system may not
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only lead to reinforcement learning deficits, but also psychotic symptoms such
as delusions as control processes are not adequately exerted in order to update
internal models of the environment (Adams, Stephan, Brown, Frith & Friston,
2013). Control-related regions such as prefrontal cortex, which also shows strong
functional connectivity with the striatum (Di Martino et al., 2008), may indeed
be involved in delusion formation and maintenance (Heinz & Schlagenhauf, 2010).
Arguably, in the absence of an adequate cognitive control mechanism regulating
bias, solely targeting subcortical dopamine with antipsychotics may not suffice to
alleviate symptoms. In contrast, NTR patients may have sufficient cognitive con-
trol such that alleviating the striatal dysfunction is sufficient to reduce symptoms
adequately.
This experiment offers the first task-related neuroimaging evidence for differen-
tial caudate function in chronic TRS and NTR patients. It has been suggested
that metabolic as well as anatomical abnormalities in the basal ganglia includ-
ing the caudate nucleus are involved in TRS and may also be associated with
clozapine response. For example, clozapine responders show hypermetabolism in
the thalamus and basal ganglia, which is reduced following successful clozapine
treatment (Rodriguez, Andree, Castejon & Garcia, 1996; Rodriguez et al., 1997).
A reduction of metabolism specifically in the caudate after clozapine response was
observed more recently (Molina, Sanz, Sarramea & Palomo, 2007) and clozapine
administration is associated with a reduction of caudate volume (Chakos, Lieber-
man, Alvir, Bilder & Ashtari, 1995; Frazier et al., 1996; Scheepers, de Wied et
al., 2001; Scheepers, Gispen de Wied, Hulshoff Pol & Kahn, 2001). Notably,
treatment responsive patients were found to have increased dopamine synthesis
capacity compared to TRS (Demjaha et al., 2012), a finding which was most
strong in the caudate nucleus. Thus the caudate may constitute an interesting
target for further investigation of TRS in studies stratifying patient subgroups by
response.
In summary, the data suggest that while the behavioral output during reward
learning of patients with treatment resistant and treatment responsive schizo-
phrenia appears to be similar, it is underpinned by different neural systems. The
data support the idea that TRS may represent a different disease from treatment
responsive schizophrenia; in line with suggestions that TRS does not fit well into
the contemporary dopaminergic dysfunction model of schizophrenia.
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Chapter 5
Experiment 3: Myelin water fraction and
its association with cognitive control in treat-
ment resistant and responsive schizophrenia
5.1 Introduction
Schizophrenia, a debilitating psychotic disorder, has been widely described in
terms of a dysconnection syndrome (Friston et al., 2016; Friston & Frith, 1995;
Volkow et al., 1988). Symptoms of psychosis, including delusions and hallucin-
ations, are in part suggested to emerge as a result of inadequate integration of
neural processes in the brain. Both functional and structural connectivity dys-
functions have been observed in schizophrenia (Pettersson-Yeo, Allen, Benetti,
McGuire & Mechelli, 2011) and it is by now widely established that white matter
abnormalities are pervasive in the disorder (Klauser et al., 2017). These have
been shown to be associated with abnormal functional activation (Marenco et al.,
2012) and connectivity (Hu Liu et al., 2011) as well as symptoms (Canu, Agosta &
Filippi, 2015). The most consistent findings show white matter changes in frontal
and temporal lobes, as well as in the corpus callosum and internal capsule (Ku-
bicki et al., 2007; Samartzis, Dima, Fusar-Poli & Kyriakopoulos, 2014; Wheeler
& Voineskos, 2014).
Most imaging studies include medicated patients and there are mixed findings re-
garding the effects of antipsychotic medication on white matter (Amato, Beasley,
Hahn & Vernon, 2016). Tishler et al. (2017) showed that myelination initially
increases within the first year of antipsychotic medication treatment, but de-
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creases thereafter. It has also been suggested that good treatment response is
associated with improved white matter integrity (Garver et al., 2008). Unfortu-
nately symptomatic non-response to treatment remains an area of unmet clinical
need, with around 30% of patients with a diagnosis of schizophrenia showing in-
adequate response despite optimal treatment (Lindenmayer, 2000; Mortimer et
al., 2010). It is therefore possible that this form of “treatment-resistant” schizo-
phrenia (TRS) constitutes a separate neurobiological disorder to treatment re-
sponsive schizophrenia, such that antipsychotic medication focussed on dopamine
receptor blockade is not targeting the underlying cause of psychosis in this patient
subgroup. Indeed, one possibility is that the abnormalities in connectivity in TRS
are of such severity that it precludes a remission of symptoms despite adequate
treatment (T. P. White et al., 2016). Specifically, it is possible that altered fronto-
striatal interactions result in dysfunctional cognitive control and that treatment
resistance arises due to a greater difficulty in integrating bottom-up sensory sig-
nals with top-down executive control, rendering dopamine D2 receptor blockade
an insufficient mechanism to reduce symptoms of psychosis. This dysconnectiv-
ity could be instantiated as a dysfunction of structural integrity of white matter
tracts; how these changes, particularly myelination, relate to TRS and cognitive
control remains unknown.
Overall there is a large body of evidence suggesting that patients with schizo-
phrenia show widespread decreases in white matter integrity, usually on the basis
of diffusion weighted imaging (Wheeler & Voineskos, 2014). The most commonly
reported measure is fractional anisotropy (FA), which indexes the degree of dir-
ectionality of diffusing water molecules. Changes in FA are attributed to changes
in the microstructure of white matter tracts; however, these could in effect be
indicators of numerous underlying features such as myelination, axon diameter,
fibre density, axon number, or axonal membrane integrity. Multicomponent driven
equilibrium single pulse observation of T1 and T2 (mcDESPOT) is a recently de-
veloped imaging technique which allows for the derivation of a whole-brain myelin
water fraction (MWF) map with rapid acquisition times (Deoni et al., 2008). As
a metric for the fraction of water trapped between the myelin sheaths around
the neuronal axons, MWF has been shown to correlate strongly with histological
measures of myelin content (Laule et al., 2006; Webb et al., 2003), and to provide
higher specificity to myelin content as compared with diffusion measures (Mädler,
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Drabycz, Kolind, Whittall & MacKay, 2008; Vavasour, Laule, Li, Traboulsee &
MacKay, 2011). This experiment is the first to report use of mcDESPOT in
a sample of patients with a diagnosis of schizophrenia, stratified by treatment
response status, and a healthy control sample.
The aims of this experiment were to test the utility of mcDESPOT in detect-
ing differences in myelination between patients with schizophrenia and healthy
controls and to investigate whether differences in myelination may account for
differences in response to antipsychotic treatment. Specifically, the hypotheses
were that:
1. Patients with schizophrenia will show reduced MWF compared to HC in
widespread areas of the brain, particularly in frontal white matter tracts
2. TRS patients will show a greater MWF deficit compared to HC, with NTR
patients at intermediate levels




mcDESPOT data was available for 22 patients fulfilling criteria for treatment
resistant schizophrenia (TRS), 21 patients with non-treatment-resistant schizo-
phrenia (NTR), and 24 healthy controls (HC).
5.2.2 Statistical analysis
5.2.2.1 Whole-brain group comparisons
Whole-brain normalised MWF maps were subjected to non-parametric permuta-
tion tests using FSL’s randomise (with 10000 permutations), and significance
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values were corrected for multiple comparisons using threshold-free cluster en-
hancement (TFCE). Clusters were defined with an extent threshold of 50 voxels.
The effect of group (HC vs. NTR vs. TRS) was tested, adjusting for effects of
age and sex.
5.2.2.2 White matter histogram analysis
In order to analyse the distribution of MWF values within the white matter spe-
cifically, MWF maps were overlaid with a white matter mask obtained from the
Johns Hopkins University White Matter Atlas. Histogram analyses of white mat-
ter MWF were conducted by summing the number of voxels for 100 uniform bins
between 0% and 30%, similar to Kolind et al. (2012). Each individual’s histo-
gram was normalised with respect to the area of the histogram. For each subject,
the mean (first moment), variance (second moment), peak position (mode), and
peak height (frequency of voxels in the modal bin) of the histogram were calcu-
lated and subsequently compared between groups. Non-parametric Kruskal Wallis
tests were used due to non-equal variances.
5.2.2.3 MWF and Stroop effect
The following analysis was conducted for the 23 HC, 21 TRS and 21 NTR patients
for whom Stroop data, as presented in Chapter 3, was available. FSL’s randomise
was used to test for a correlation between whole-brain MWF and the RT Stroop
effect across all subjects. For the resulting significant cluster, each subject’s mean
MWF was extracted and compared between groups. Following this, a mediation
analysis was conducted to test whether MWF in this region mediated group dif-
ferences in the RT Stroop effect. A bootstrap approach proposed by Preacher
and Hayes (2004) was used in order to test for significance of the indirect effect
of group on RT Stroop effect.
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5.3 Results
5.3.1 Whole-brain group comparisons
At whole-brain level, controlling for sex and age, there was a significant effect of
group in four clusters (Figure 12): two large clusters covering much of the right
and left subcortical white matter including the inferior fronto-occipital fasciculi,
particularly in the vicinity of the striatum and extending to the cerebellum, one
cluster containing the left putamen, and a small cluster in the right subcallosal
cortex (Table 8). In each of these clusters, post-hoc t-tests revealed that both
NTR and TRS patients showed reductions compared to HC, all ps< .05, with
no difference detected between the two patient groups, all ps> .05. Mean MWF
within these clusters ranged from 6% to 19% – lower than the expected range for
white matter – indicating partial voluming effects within the significant voxels.
Figure 12. Main effect of group on myelin water fraction. Maps reflect
threshold-free cluster enhancement corrected p-values.
5.3.2 White matter histogram analysis
Group histograms (depicted in Figure 13) show that voxel count peaks in the
expected range for white matter (25-30%), consistent with previous mcDESPOT
reports. Both patient groups show shifts slightly downwards and to the left,
suggesting that less voxels within the white matter fall into the normal region of
MWF values.
Table 9 shows Kruskal-Wallis test statistics for the effect of group on histogram
metrics. Post-hoc Mann-Whitney tests (Bonferroni corrected for multiple compar-
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Table 8
Significant clusters of group differences in myelin water fraction
Region Side k p MNI
Subcallosal cortex R 52 .026 8 18 -24
Putamen L 189 .035 -26 6 -6
Putamen L -26 14 0
Putamen L -20 4 2
Inferior fronto-occipital fasciculus L 2875 .01 -32 -18 -2
Inferior fronto-occipital fasciculus L -34 -28 -12
Internal capsule L -24 -18 4
External capsule L -32 -6 4
Inferior longitudinal fasciculus L -38 -50 -20
Inferior longitudinal fasciculus L -34 -50 -12
Cerebellar white matter R 4278 .016 44 -68 -36
Cerebellar white matter R 6 -44 -26
Cerebellar white matter R 30 -18 2
Cerebellar white matter R 44 -58 -38
Cerebellar white matter R 46 -74 -36
Cerebellar white matter R 34 -52 -26
isons) showed that histogram means were significantly lower in TRS compared to
HC (W =374, p= .045), and marginally lower in NTR compared to HC (W =353,
p= .064). The variance was greater in both NTR and TRS compared to HC, all
ps< .05. Peak height was reduced in both patient groups compared to HC, al-
though these tests did not survive corrections for multiple comparisons. There
were no differences between NTR and TRS groups on any of the histogram meas-
ures.
Table 9
Means and standard deviations of histogram data per group
HC NTR TRS
M SD M SD M SD
X 2 (2) P
Mean 24.19 0.98 23.33 1.30 23.31 1.24 7.61 .022
Variance 24.02 4.57 28.93 4.71 27.90 5.00 13.49 .001
Mode (peak position) 27.46 1.18 27.15 1.39 26.89 1.33 2.23 > .05
Mode frequency
(peak height)
0.17 0.04 0.14 0.03 0.14 0.03 6.98 .031
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Figure 13. Normalised histograms of white matter myelin water fraction by
group. Histograms are graphically smoothed in R (smoothing parameter 0.35)
5.3.3 MWF and Stroop effect
A large cluster consisting of the corpus callosum (genu, body, and splenium) was
negatively related with RT Stroop effect across all subjects, such that higher MWF
values were associated with a smaller Stroop effect (Figure 14). Mean MWF from
within this significant cluster was extracted for each subject for further analyses.
The negative correlation was evident within each group separately (HC: R=-0.35,
p= .09; NTR: R=-0.50, p= .021; TRS: R=-0.59, p= .005). Pairwise compar-
isons of mean MWF in the corpus callosum between HC and the two patient
subgroups did not survive Bonferroni corrections for multiple comparisons; hence
NTR and TRS patients were pooled into a single schizophrenia (SZ) group for the
mediation analysis. A mediation analysis tested whether corpus callosum MWF
mediated group differences in the Stroop effect according to the Baron and Kenny
steps (Baron & Kenny, 1986; Figure 15). Regressing the Stroop effect on group
(HC vs. SZ) showed a significant effect of group (path c’: β =93.08, SD=28.93,
p= .002). Regressing corpus callosum MWF on group showed a significant ef-
fect of group, (path a: β =-0.01, SD=0.01, p= .019), with higher MWF in HC
(M =0.20, SD=0.1) compared to SZ (M =0.19, SD=0.17). Finally, regressing
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the Stroop effect on both group and corpus callosum MWF revealed a signific-
ant effect of MWF (path b: β =-3534.33, SD=765.24, p< .001). The effect of
group (β =60.42, SD=26.13, p= .02), though significant, was reduced compared
to the simple model regressing the Stroop effect on group alone. An analysis of
the indirect effect (defined as the product between the effect of group on MWF
and the effect of MWF on RT Stroop, controlling for group) was performed with
non-parametric bootstrapping of the sampling distribution using 5000 bootstrap
samples (Preacher & Hayes, 2004). This revealed a significant indirect effect (95%
confidence interval [4.69, 67.50]); suggesting that there was a partial mediation of
the effect of group on Stroop effect by corpus callosum MWF.
Figure 14. Significant cluster of whole-brain analysis of correlation between
Stroop effect and myelin water fraction. Maps reflect threshold-free cluster
enhancement corrected p-values.
5.3.4 Relationship with clinical variables
For each of the four significant clusters from the whole-brain MWF group analysis
as well as the corpus callosum cluster from the Stroop analysis, an exploratory
analysis of MWF was conducted for correlations with PANSS positive symptom
score, PANSS negative symptom score, illness duration, and CPZ equivalent med-
ication dosages, both across all patients as well as within the two patient groups
separately. No correlation was significant, all ps> .05 (uncorrected for multiple
comparisons).
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Figure 15. Mediation diagram of the association between group, Stroop effect,
and callosal myelin water fraction
5.4 Discussion
In this experiment, mcDESPOT imaging (Deoni et al., 2008) was applied to a
sample of patients with a diagnosis of schizophrenia, stratified by treatment re-
sponse, and healthy controls. The results show that this method is sensitive to
reductions in myelin water fraction (MWF) in schizophrenia compared to healthy
controls, with the greatest effect evident in areas surrounding bilateral striatum,
particularly the inferior fronto-occipital fasciculus, as well as the cerebellum. Re-
ductions in the patient groups were bilateral but with larger clusters observed
within the left cerebral hemisphere. The findings of reduced MWF in the in-
ferior fronto-occipital fasciculus is consistent with DTI based results of reduced
fractional anisotropy in this tract (S.-H. Lee et al., 2013; X. Liu et al., 2013;
Epstein et al., 2014; Ćurčić-Blake et al., 2015). The inferior fronto-occipital fas-
ciculus connects the occipital and temporal lobes with orbitofrontal areas and is
an important aspect of both the language and visual networks (Catani, Howard,
Pajevic & Jones, 2002). Thus, impaired information flow along the tract due to
impaired white matter may be involved in auditory or visual hallucinations and
has also been associated with cognitive impairments in schizophrenia (X. Liu et
al., 2013). Mean MWF in the areas showing significant reductions in patients
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were below the expected range for white matter, thus suggesting that the reduc-
tions included both white and grey matter voxels. Histograms of MWF restricted
to the white matter tracts allowed for a closer comparison of the distribution of
values specifically in the white matter between the three groups, confirming that
patients’ histograms were shifted towards lower MWF values, with a greater vari-
ance compared to healthy controls. MWF did not, however, distinguish between
the two patient subgroups, consisting of treatment resistant (TRS) and treatment
responsive (NTR) schizophrenia patients. This suggests that underlying abnor-
mal myelination is not a driving force behind antipsychotic treatment resistance
at the chronic stage of the illness.
There was a correlation between performance on the Stroop task, a standard
measure of executive control, and corpus callosum MWF, whereby greater MWF
values were associated with a smaller reaction time interference effect. This asso-
ciation was observable both across all subjects and within all groups separately.
A mediation analysis showed that MWF in the corpus callosum partially medi-
ated the group difference on the Stroop task, such that lower MWF in patients
accounted in part for the greater interference effects seen in this sample compared
to controls.
The finding of reduced MWF in patients with schizophrenia compared to healthy
controls is in line with a large body of evidence suggesting impaired white matter
integrity in the illness (Fitzsimmons et al., 2013; Kubicki, McCarley & Shenton,
2005; Pettersson-Yeo et al., 2011). The proliferation of diffusion weighted imaging
reports in recent years has shed enormous light on disturbances of white matter
in psychosis and schizophrenia on a whole-brain basis, yet a remaining disadvant-
age of the technique is the large number of microstructural factors which could
contribute to the signal. Multicomponent relaxation imaging allows for a more
myelin-specific quantification of the dysfunction in vivo. The mcDESPOT pro-
tocol is such a technique which has recently been validated pre-clinically (Wood
et al., 2016), and this is the first report to use this technique in chronic patients
with a diagnosis of schizophrenia, with an additional stratification by treatment
response status. The mechanisms underlying resistance to antipsychotic medica-
tion are as yet not well understood (Mouchlianitis et al., 2016), but the lack of
response despite adequate dopamine D2 receptor occupancy in TRS (Coppens et
al., 1991; Wolkin et al., 1989) suggests that striatal hyperdopaminergia may not
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be the principal aetiology of psychotic symptoms in this patient subgroup. One
study investigating white matter microstructure found reduced fractional aniso-
tropy and increased radial diffusivity in the corpus callosum in chronic treatment
resistant patients as compared to healthy controls (Holleran et al., 2014); however
this study did not include a remitted patient group and as such the specificity of
the finding to TRS is unclear. On a functional connectivity level, a recent report
by T. P. White et al. (2016) suggested that divergent pathophysiologies of stri-
atal resting-state connectivity are present in treatment resistant and treatment
responsive schizophrenia. In addition, Sarpal and colleagues demonstrated that
functional striatal resting-state connectivity may be predictive of treatment re-
sponse in first-episode psychosis patients (Sarpal, Argyelan et al., 2015). The data
from the current experiment suggest that these findings of functional connectivity
differences are not mirrored by myelin water fraction differences. In this chronic
patient sample, the effects of illness chronicity and exposure to medication can by
definition not be entirely disentangled from the effects of interest and therefore
remain as potential confounds. However, the absence of group difference on these
variables as well as the lack of association with myelin water fraction suggest that
it is unlikely that these effects are masking true differences in myelination between
treatment resistant and responsive patients. Nevertheless, future research could
usefully examine these issues by applying the technique to patients at an earlier
stage of the illness.
Cognitive deficits are considered a core feature of TRS (Buckley & Shendarkar,
2005). Cognitive control further relies on intact connectivity of the underlying
neural network (Cole, Yarkoni, Repovs, Anticevic & Braver, 2012; Hwang, Velan-
ova & Luna, 2010); hence the aim of this experiment was to assess how both
cognitive and structural mechanisms relate to treatment response. As described
in detail in Chapter 3, there were no differences in reaction time interference on
the Stroop task between the two patient groups. Thus on a behavioural level,
treatment resistance does not seem to be associated with exacerbated cognit-
ive control deficits at the chronic stage of the illness. However, callosal myelin
reductions in schizophrenia patients partially mediated performance differences
compared to healthy individuals. Impaired white matter integrity in the corpus
callosum reductions have been widely observed in the illness, but this is the first
report of a direct link between a measure of callosal myelination and cognitive
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control function in schizophrenia.
Despite a growing literature on mcDESPOT and recent pre-clinical validation
(Wood et al., 2016), it is a relatively new technique which requires further evalu-
ation by independent groups. It has as yet not been extensively applied to many
neuropsychiatric disorders and as such there are limitations to the interpretability
of the results in terms of specificity to schizophrenia. However taken together, this
experiment suggests that mcDESPOT is a suitable method to detect myelin al-
terations in schizophrenia, clarifying the nature of the changes reported in earlier
DTI studies, and this may be a relevant marker in terms of cognitive control per-
formance in patients. However, this study did not uncover more severe myelin
abnormalities in treatment resistant patients compared to treatment responsive
patients, suggesting that primary differences in treatment response and functional




6.1 Summary of findings and implications
The purpose of this thesis was to examine the neural mechanisms of treatment
response in psychosis within a framework of cognitive control. The underlying hy-
pothesis was that an inability to exert cognitive control, particularly in the context
of feedback learning, would account for the lack of symptomatic response to an-
tipsychotic medication in patients with treatment resistant schizophrenia (TRS).
The expectation was furthermore that this dysfunction would be characterised
by exacerbated dysconnectivity both on a functional and structural neural level
in TRS patients compared to patients with non-treatment-resistant schizophrenia
(NTR) and healthy controls (HC).
6.1.1 Experiment 1
In the first experiment, subjects performed a verbal Stroop task while undergoing
functional magnetic resonance imaging (fMRI). On a behavioural level, as expec-
ted, both patient groups showed increased interference effects compared to HC.
This was evident both in the accuracy and reaction time (RT) data of the task.
This finding is consistent with previous evidence for deficits in cognitive control
in schizophrenia (Westerhausen et al., 2011). However, contrary to expectations,
NTR and TRS patients did not differ with respect to the extent of the dysfunc-
tion, exhibiting similar accuracy and RT interference Stroop effects. Thus, on this
basic level of cognitive control, TRS patients do not appear to be more severely
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impaired compared to remitted patients. The average neural activation during
the Stroop task mirrored these behavioural findings, in that NTR and TRS pa-
tients did not differ from one another but, as a group, showed some abnormal
activation compared to HC. On incongruent (vs. congruent) trials, a contrast
which is thought to capture response conflict most potently, patients showed hy-
peractivation of the supplementary motor cortex (SMA). This finding replicates
results from a recent meta-analysis (Minzenberg et al., 2009) reporting increased
activation in this region in schizophrenia on tasks of executive function. This
hyperactivation may reflect a compensatory response to increased interference, in
line with suggestions of inefficient cortical processing. Moreover, hypoactivations
were evident in superior parietal cortex as well as the insula during incongru-
ent trials. These regions constitute core nodes of the fronto-parietal and salience
networks, respectively, which are thought to jointly coordinate flexible execut-
ive control (B. D. Peters et al., 2008). As this dysfunction was evident on the
simple contrast of incongruent trials, they may reflect more general control related
demands beyond response conflict.
Importantly, this experiment identified a region in rostral ACC which differen-
tiated NTR and TRS groups in terms of how psychotic symptoms related to
neural activation. While NTR patients showed increased neural activation with
increasing symptoms, potentially also reflecting a compensatory mechanism, TRS
patients showed an inverse relationship between activation and symptoms. Cru-
cially, the ensuing hypoactivation in the most symptomatic TRS patients pre-
dicted a deterioration in performance as measured by RT. This association estab-
lishes a direct link between symptoms, neural activation, and behaviour which is
specific to TRS, thus providing evidence for distinct abnormal mechanisms in this
patient group. Finally, an exploratory analysis was performed in order to assess
whether connectivity of the identified ACC region with subcortical nodes of the
cognitive control network was also more impacted in TRS patients. Indeed, there
was a tendency towards reduced functional connectivity between ACC and dorsal
thalamus in TRS compared to HC, while NTR patients showed normal functional
connectivity.
Although the finding of reduced functional connectivity in TRS is only margin-
ally significant, it provides novel insights into potential dysfunctional mechanisms
which may drive resistance to antipsychotics. Cortical-subcortical interactions
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play an important role in psychotic symptom formation, and structural as well as
resting state dysconnectivity have previously been implicated in TRS (Pettersson-
Yeo et al., 2011). However, this is the first study to link task-related connectivity
to treatment response status, suggesting that dysconnectivity underlying cog-
nitive control deficits may be specifically involved in non-response. Specifically,
antipsychotics may normalise subcortical hyperdopaminergia in TRS, but in the
absence of normal integrative processes with prefrontal cortical regions symptoms
may persist despite treatment. Alternatively, TRS may not present with abnormal
subcortical dopamine function (Demjaha et al., 2014), rendering antipsychotics
largely ineffective in their primary aim.
6.1.2 Experiment 2
The second experiment aimed to probe a dopamine-dependent cognitive process
in TRS, NTR, and HC, while linking this process to cognitive control. In a further
fMRI experiment, subjects performed a reward learning task which allowed for
computational modelling of their behaviour using a reinforcement learning (RL)
model. Similarly to the Stroop task, both patient groups performed more poorly
compared to HC, but did not differ from each other. Specifically, patients made
fewer ideal choices, as determined by the RL model, compared to HC. This finding
is in line with a large literature on impaired feedback learning in schizophrenia.
The study further replicated previous findings of an emotional bias toward happy
faces over angry faces in this task across patients and controls (Evans et al., 2011).
Subjects were, on average, more likely to select a happy face despite feedback
evidence being in favour of the angry face than to select an angry face when the
evidence is in favour of the happy face. This bias did not differ between groups.
Reward prediction error (RPE) was computed on a trial by trial basis for each
subject, and the associated neural activation compared between groups. As hy-
pothesised, NTR patients specifically showed abnormal RPE-related activation
compared to HC both cortically and subcortically. In contrast, TRS patients
did not differ from HC. Abnormal RPE-related activation has previously been
reported in schizophrenia and interpreted as an indicator of dopaminergic dys-
function (Corlett et al., 2007). This finding therefore supports the hypothesis
that a dopaminergic abnormality is selectively present in NTR patients, while
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TRS patients show normal dopamine function. The results are in line with re-
cent PET imaging data (Demjaha et al., 2014) and provide the first task-related
evidence to support this notion.
Since reinforcement learning is underpinned to a large extent by similar neural
networks as cognitive control processes, the secondary aim was to assess whether
groups differed in how cognitive bias modulated the feedback-related neural re-
sponse. The premise of this analysis was that in emotional blocks, subjects would
have to exert more cognitive control compared to neutral blocks in order to over-
come their bias and learn adequately from the reward feedback. Due to the over-
arching hypothesis of exacerbated cognitive control dysfunction in TRS it was
expected that emotional bias would have a larger impact on RPE-related signal
in this group. Indeed, a stronger emotional bias in TRS predicted a stronger RPE
signal in bilateral thalamus and caudate nucleus in response to losses. In con-
trast, NTR patients showed an inverse association between bias and RPE signal.
Importantly, the correlation differed significantly between the two patient groups.
The positive association in TRS specifically on trials on which subjects received
negative feedback suggests that subjects were more surprised by this feedback
when they had a strong prior bias. Thus, predictions about reward values appear
to suffer most in these subjects. In contrast, NTR patients did not show this
association. In summary, the results suggest that while in NTR patients the RPE
signal itself is impaired, TRS patients show normal RPE signalling but a greater
difficulty in making appropriate predictions with stronger emotional bias.
6.1.3 Experiment 3
In the final experiment, subjects underwent multicomponent driven equilibrium
single pulse observation of T1 and T2 (mcDESPOT) imaging. The aim was to
compare myelin water fraction (MWF) between groups in order to determine
whether TRS is characterised by an exacerbated abnormality in myelin content
compared to NTR and HC. In addition, the experiment aimed to establish whether
differences in MWF would account for deficits in cognitive control as measured
by the Stroop task. In line with longstanding evidence for white matter abnor-
malities in schizophrenia, both patient groups showed extensive MWF reductions
compared to HC. However, contrary to expectations, there were no significant
101
differences in MWF between NTR and TRS patients.
With respect to cognitive control, MWF in the corpus callosum was significantly
related to Stroop task performance across and within groups. Since the NTR and
TRS patient groups did not differ in terms of MWF or Stroop performance, they
were pooled into a single patient group for the subsequent mediation analysis.
In line with expectations, callosal MWF partially mediated differences between
patients and controls on the Stroop task; providing evidence that cognitive con-




A limitation of this study is its cross-sectional design, restricting the interpretabil-
ity of the results to some extent. Patients were classified as treatment resistant or
treatment responsive based on their current psychotic symptoms and medication
history; however, it is unclear how symptomatic patients were at illness onset.
Longitudinal study setups allow for an assessment of symptom change which can
subsequently be related to change in task performance and activation; however
this comes at the risk of problems such as attrition or practice effects. As part of
a larger funded project, this study was set up as a cross-sectional design in order
to identify potential biomarkers which can be applied to the analysis of data from
first episode psychosis (FEP) patients in a longitudinal study setup.
In addition it is possible that the sample size in this study was not sufficient
to detect subtle differences between the two patients groups. A sample size of
approximately 20 per group is reflective of the typical sample size in many fMRI
studies in the field of psychiatry; however, the NTR and TRS groups included
in this study are likely to have higher similarity to each other than to healthy
controls, thus potentially requiring larger samples in order to differentiate them
statistically. The possibility can therefore not be excluded that a lack of difference
in mean neural activation or myelin water fraction may be due to a lack of power.
However, with respect to the functional tasks, the descriptive behavioural data
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does not suggest a clear tendency toward group differences.
An alternative possible explanation for the absence of group differences in task
performance lies in the experimental setup of the tasks themselves. The verbal
Stroop task is a standard measure of executive function and reflects on a very
basic level cognitive control in the context of interference. It is possible that
an alternative experimental paradigm of cognitive control may have been more
sensitive to potential group differences. For example, a speeded motor response
task such as the Eriksen Flanker task may set up a stronger response conflict and
therefore differentiate more easily between groups.
Furthermore, a major drawback of the Faces task is the relatively low number of
trials per block. This precluded an estimation of RL model parameters (learning
rate and inverse temperature) on a single subject level. Parameter estimation
on a group level is common in the fMRI literature (Gläscher, Daw, Dayan, &
O’Doherty, 2010; Schönberg, Daw, Joel, & O’Doherty, 2007), and allows for an
estimation of subject-specific trialwise prediction errors nevertheless, but limits
the utility of the estimated parameters themselves for group comparisons. In
addition, as the Faces task used reward contingencies of 40% and 60% for the two
stimuli, it constitutes a rather difficult task which does not leave a large range
within which to perform above chance level. Observable group differences on this
task are therefore necessarily relatively small, and as such this task may not allow
for enough variation in performance to detect small differences reliably.
6.2.2 Inclusion and exclusion criteria
The definition of TRS criteria has been a point of debate in the literature (Suzuki
et al., 2011). The primary aim of recruitment criteria in this study was to identify
a group of patients who had not responded to antipsychotic treatment and a group
of patients in symptomatic remission, while holding as many potential confound-
ing factors constant as possible. Therefore, patient groups were well matched on
illness duration, age of onset, current medication dosage, age, and sex. While this
avoids a number of confounds, an argument can be made that TRS criteria were
not strict enough to ensure clearly defined groups. Consensus guidelines have
more recently been presented (Howes et al., 2016) which include several criteria
that were not met in the current study. For example, not all TRS patients were
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currently or previously prescribed antipsychotics at dosages equivalent to 600 mg
CPZ daily; instead, it was ensured that dosages were above the minimum effect-
ive dosage (Leucht et al., 2014). Had patient groups been defined partly on the
basis of their medication dosage, they would have likely differed substantially on
this variable. This type of pre-existing group difference which is essentially a de-
fining characteristic of group membership cannot be statistically “controlled for”
with analysis of covariance (ANCOVA), as has been argued elegantly elsewhere
(Suckling, 2011; G. A. Miller & Chapman, 2001), despite a common practice to
attempt to do so. The less stringent inclusion criteria used in this study therefore
attempted to avoid the potentially confounding effects of medication dosage. In
a similar vein, patients currently on clozapine were excluded so as to avoid po-
tentially differential effects of clozapine as compared to other antipsychotics on
the brain, as well as to avoid the introduction of sub-groups of patients refractory
to clozapine (super-resistant patients). Importantly, these issues highlight a more
general difficulty in schizophrenia research stemming from the heterogeneity of
the illness. The clinical presentation of schizophrenia varies widely across affected
idividuals and therefore subsampling representative groups of patients remains a
substantial challenge in this field of research.
The exclusion of clozapine patients raises the question of why the included TRS
patients were not prescribed clozapine, if they were indeed treatment resistant. In
fact, a number of these patients (n=4) had previously been prescribed clozapine,
but treatment had been discontinued at least 2 years before study participation.
It is possible that some patients were unwilling to take clozapine or were not
offered the opportunity, in line with reports that clozapine is underprescribed in
the UK (Howes et al., 2012).
Necessarily this study may entail a selection bias of patients suitable for scanning,
who may not be reflective of the overall population of diagnosed schizophrenia
patients.
6.2.3 Potential confounds
As described above, patient groups were well matched for a number of clinical
variables including illness duration, age of onset, and current medication dosage.
However, cumulative lifetime medication exposure was not assessed as historical
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records were not available for many patients due to the relatively long illness
duration. It is likely that TRS patients would have been exposed to more med-
ications at higher doses over the course of their lifetime, but it is unclear how
this may impact on the functional and structural measures assessed in this study.
Cumulative medication exposure therefore remains a possible confound.
Due to the nature of TRS and NTR criteria in this study, group membership is
inextricably linked with symptoms of psychosis. Indeed the main defining differ-
ence between groups was psychosis severity, thus rendering psychotic symptoms
a further potential confound. This is of particular relevance in the Stroop fMRI
data analysis, which yielded a significantly different effect of psychotic symptoms
on ACC activation in the two patient groups. In fact it may be argued that the
observed effect arose as a function of psychosis rather than of treatment response
status itself. To resolve this issue it would be necessary to assess the relation-
ship between neural activation and psychosis in symptomatic patients who later
respond well to treatment; a procedure which is planned in the context of a
follow-up study in FEP patients. Nevertheless, given that the identified cortical
region in the current study proved to be behaviourally relevant specifically in the
TRS group, it seems likely that the finding reflects at least partially an effect of
treatment response.
Patients and healthy controls differed significantly in terms of IQ as measured by
the WASI. This is reflective of a common observation in studies of schizophrenia.
Premorbid IQ score is a known indicator of risk for schizophrenia (Woodberry, Gi-
uliano & Seidman, 2008). Thus, patient and control samples matched for IQ would
likely constitute an inaccurate representation of the true population distributions,
calling into question the ecological validity of subsequent research outcomes. It is
also worth noting that IQ may be underestimated in patients with schizophrenia
when using standardised batteries such as the WASI, since effects of motivation
or poverty of speech (associated with negative symptoms) are likely to play a
role. In this study IQ was not related to neural activation or myelin content in
areas identified as relevant to diagnostic or treatment response status, however
the possibility of confounding effects cannot be entirely excluded. Nevertheless,
it stands to reason that entirely removing effects of IQ in itself may not be a
desirable aim given the relevance of cognitive abilities to the clinical presentation
of schizophrenia.
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Similarly, as can be seen in Table A.7, groups differed significantly in terms of
depression as measured by the Beck Depression Inventory (BDI). A confounding
effect of depression severity on the current results can therefore not be excluded.
It is possible that depression may impact on cognitive performance and there-
fore be associated with some of the observed behavioual differences in this study.
However, it is unlikely to explain the between-patient differences in neural activ-
ation related to reward prediction error. Depression has been associated with a
blunted RPE response (Kumar et al., 2008), thus if depression were driving group
differences one would expect the TRS group (showing the highest BDI score) to
exhibit a more blunted RPE signal compared to NTR. However, the inverse was
observed, rendering a driving effect of depression unlikely.
6.3 Conclusion
The work presented in this thesis examined treatment resistant schizophrenia in
the context of cognitive control, reinforcement learning, and structural connectiv-
ity. As such, it provided a systems neuroscience perspective on TRS, taking into
account possible dysfunctions on a functional cognitive as well as a neuroana-
tomical level. The primary question driving the presented research was: is TRS
characterised by a categorically distinct neuropathology from treatment respons-
ive schizophrenia; and is this expressed in observable ways on the neural and
behavioural level during cognitive tasks? The overarching hypothesis was that an
exacerbated cognitive control dysfunction in TRS would lead to inadequate integ-
ration of top-down cognitive processes with ongoing incoming information (e.g.
reward feedback), resulting in an abnormal representation of the surrounding en-
vironment and thus psychotic symptoms such as delusions and hallucinations.
This dysfunction was hypothesised to be reflected in task-related hypoactivation
particularly of the frontal cortex as well as functional and structural dyscon-
nectivity in TRS compared to treatment responsive schizophrenia. Symptoms of
psychosis would thus be perpetuated in these patients despite treatment with an-
tipsychotic medication, which primarily targets the subcortical dopamine system.
While the patient groups included in this study did not show immediate differ-
ences in cognitive control related behaviour or neural activation, the results imply
a more complex pattern of differences. Rather than simple differences in mean
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activation, differences between groups emerge when relating task activation to
symptom severity, prediction error, and cognitive bias. This suggests that similar
behavioural output may be underpinned by different modulatory mechanisms in
the brain. This is consistent with the notion that a similar clinical presentation,
resulting in a shared diagnosis of schizophrenia, may be underpinned by different
neural abnormalities in treatment resistant and treatment responsive patients.
The results presented in this thesis point toward reduced cognitive control related
frontal activation in highly symptomatic TRS patients, as well as reduced fronto-
thalamic functional connectivity specifically in TRS. However this specificity is
not mirrored on a structural level in terms of myelination. A possible explanation
for this is that the exacerbated dysconnectivity operates at the level of the syn-
apse rather than in terms of anatomical abnormalities of white matter tracts. It
has previously been argued that aberrant synaptic plasticity, rather than struc-
tural connectivity changes, are likely to drive symptoms of psychosis (Stephan,
Baldeweg & Friston, 2006; Friston et al., 2016). It is thus possible that patients
fall on a continuum of synaptic dysconnectivity, with more severe abnormalities
leading to treatment resistance. While dysconnectivity may be the result of a
dopaminergic dysfunction in some patients, it may arise from abnormalities in
alternative neurotransmitter systems in others (e.g. acetylcholine, Stephan et al.,
2006). The results presented in this thesis furthermore lend support for the hy-
pothesis that TRS patients do not exhibit the dopamine dysfunction classically
associated with schizophrenia.
This work offers the first account of an explicit comparison between two chronic
schizophrenia patient groups who differed only in their treatment response status
during task-related fMRI as well as mcDESPOT imaging. While these procedures
will need to be applied in a longitudinal setting, the findings provide a useful
insight into treatment response at the chronic stage of the illness as well as the
suitability of the methods in these patient groups. The study also highlights the
importance of examining group differences beyond mean activation comparisons,
particularly in highly similar clinical samples which may be differentiated by more
subtle changes that are not categorical in nature.
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6.4 Future directions
First and foremost, it will be crucial to assess neural functioning in the context
of cognitive control in patients with FEP in a longitudinal study setup. The
project from which data was presented in this thesis is currently in a second
phase of recruitment, whereby 100 FEP patients are undergoing the identical
imaging protocol. All patients will be followed up at 6 and 12 months, with a
second scan conducted during the final visit. This design will allow for the results
obtained in the chronic patient sample to be tested prospectively in the FEP
patients. Specifically, measures of cognitive control, reinforcement learning, and
myelination will be tested for their ability to predict treatment response after
one year and beyond, using results from the work presented in this thesis to
inform data analyses. Generally speaking, further research could usefully address
potential confounds of medication exposure, illness duration and levels of psychosis
by studying these measures in a longitudinal setup in FEP patients.
In light of the various effects antipsychotic medication can have on brain func-
tion and structure, studying initially antipsychotic naive patients is an important
aspect of research into treatment response. The focus should lie in identifying
biomarkers of treatment response at an early stage in the illness – after occurrence
of a first psychotic episode or even in the prodrome – that will allow for adaptive
treatment options, ideally offering a possibility to fast-track a subset of patients
to clozapine. However, in order to fully understand the mechanisms underly-
ing treatment response in psychosis, more research on the cognitive mechanisms
involved in the development of psychosis in treatment resistant and treatment
responsive schizophrenia is necessary. Within a framework of cognitive control, it
will be important to incorporate varying levels of complexity in order to establish
the most sensitive measures in these highly similar patient groups. For example,
the difficulty of speeded response tasks including distractor stimuli may be ma-
nipulated by varying the trial durations. The N-back task furthermore offers a
useful tool of executive functioning at increasingly difficult levels. Given the po-
tentially differential associations between task performance and neural activation
or clinical variables, tasks allowing for a wide performance range (e.g. probabilis-
tic learning tasks with more divergent reward contingencies than those used in
the current study) can be utilised. In addition, given the mounting evidence for
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a divergent pathology at the neurochemical level (Egerton et al., 2012; Demjaha
et al., 2014), future research will need to examine interactions between different
neurotransmitter systems (e.g. the glutamate and dopamine system), and as-
sess whether certain neurotransmitters differentially modulate cognitive function
in different patient subgroups. Multimodal neuroimaging studies including both
MRI and PET are highly useful in this regard.
The predominant challenge for future research will be to establish study designs
which are able to detect subtle and complex differences between treatment res-
istant and treatment responsive schizophrenia. The pattern emerging from the
research presented in this thesis is that rather than clear differences in average
behaviour or neural activation, these patient groups differ primarily in the modu-
latory mechanisms acting on the neural circuits relevant to different cognitive do-
mains. In terms of studying modulatory influences on synaptic connectivity with
noninvasive neuroimaging, EEG may represent a valuable tool. The mismatch
negativity (MMN), a negative potential elicited by deviant stimuli (usually in an
auditory oddball paradigm), is a well-established marker of N-methyl-D-aspartate
(NMDA) receptor activity and has been extensively studied in schizophrenia, with
consistent reductions of the MMN observed in patients compared to healthy con-
trols (Umbricht & Krljes, 2005; M. Lee et al., 2017). Reductions in the MMN are
associated with poor functioning in chronic schizophrenia (Light & Braff, 2005b,
2005a). As an indicator of perceptual learning and NMDA-mediated plasticity,
the MMN may provide useful insights into the neuromodulatory mechanisms un-
derlying antipsychotic treatment response.
However, neuroimaging techniques are not able to detect schizophrenia-related
changes on a cellular or molecular level. A promising tool in this regard is the
study of human induced pluripotent stem cells (hiPSC; K. Takahashi & Yaman-
aka, 2006, K. Takahashi et al., 2007). Recent advances in this domain have
allowed for modelling of neural development in neuropsychiatric disorders such as
schizophrenia (Ardhanareeswaran, Mariani, Coppola, Abyzov & Vaccarino, 2017),
while being able to carefully disentangle genetic and environmental influences.
Notably, findings from the first hiPSC model of schizophrenia included reduced
neuronal connectivity as well as decreased glutamate receptor expression; abnor-
malities which were subsequently responsive to treatment with the antipsychotic
loxapine (Brennand et al., 2011). The technique may provide an opportunity to
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assess cellular changes and trajectories of brain development in treatment res-
istant and responsive schizophrenia while keeping constant many potential con-
founding factors such as medication exposure and illness duration. In addition,
hiPSC-related methodologies have great potential for informing the discovery and
development of drugs for treatment of psychosis (Y. Sun & Dolmetsch, 2016).
Despite extensive research on task-related neural activity in schizophrenia, studies
typically do not use stratifiers related to treatment response to reduce the hetero-
geneity of the sample and are likely combining neurobiologically distinct subtypes
of schizophrenia. This not only clouds studies of mechanism, but potentially also
of treatment trials; missing effects that are specific to one or the other subset of
patients (Joyce, Kehagia, Tracy, Proctor & Shergill, 2017). There is an urgent
need for stratification of patients by response; both at the chronic stage of the
illness and in patients suffering a first episode of psychosis. The separation of
schizophrenia subgroups will allow the development of clearer hypotheses into the
neural mechanisms underlying antipsychotic treatment response and potentially
move us closer to being able to use these biomarkers to tailor treatment in a more
personalized and effective manner.
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Appendix
Figure A.1. Subcortical region of interest mask consisting of bilateral thalamus
and striatum (nucleus accumbens, caudate nucleus, pallidum, and putamen)
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Table A.1
Significant clusters of activation across groups for the Stroop contrast
Region Side k z MNI
Supplementary motor area L 1587 5.23 -6 4 56
Supplementary motor area R 8 4 58
Supplementary motor area R 4 0 64
Paracingulate gyrus L -6 20 42
Paracingulate gyrus R 12 20 44
Paracingulate gyrus R 8 14 46
Precentral gyrus L 2656 5.43 -48 -12 40
Precentral gyrus L -56 -6 48
Precentral gyrus L -50 -10 36
Postcentral gyrus L -64 -4 18
Postcentral gyrus L -54 -8 24
Precentral gyrus L -58 -4 20
Precentral gyrus R 1577 5.5 58 -6 40
Postcentral gyrus R 62 -6 40
Precentral gyrus R 58 -4 46
Precentral gyrus R 62 -2 20
Precentral gyrus R 50 -4 58
Postcentral gyrus R 52 -8 60
152
Table A.2
Significant clusters of activation across groups for the Incongruent contrast
Region Side k z MNI
Superior frontal gyrus L 3163 5.13 -24 -28 44
Middle frontal gyrus R 26 28 46
Superior frontal gyrus R 26 28 52
Frontal pole L -8 48 42
Middle frontal gyrus L -32 26 46
Frontal pole L -18 40 42
Postcentral gyrus L 38972 8.21 -58 -6 16
Postcentral gyrus L -42 -14 34
Postcentral gyrus L -64 -16 24
Occipital pole R 24 -98 -8
Superior temporal gyrus L -42 -30 12
Superior temporal gyrus R 14992 8.21 64 -22 4
Precentral gyrus R 64 0 14
Superior temporal gyrus R 66 -10 6
Superior temporal gyrus R 62 -8 8
Supramarginal gyrus R 38 -30 16
Postcentral gyrus R 68 -12 12
Precuneus cortex L 8003 5.72 -8 -58 18
Precuneus cortex L -6 -56 22
Precuneus cortex R 8 -58 22
Lateral occipital cortex R 48 -76 28
Precuneus cortex R 6 -56 16
Lateral occipital cortex R 52 -70 26
Lateral occipital cortex L 1196 5.57 -42 -76 34
Lateral occipital cortex L -42 -80 30
Lateral occipital cortex L -44 -72 32
Lateral occipital cortex L -42 -72 28
Lateral occipital cortex L -48 -70 28
Lateral occipital cortex L -54 -78 18
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Table A.3
Significant clusters of reward prediction error related activation during wins in
healthy controls
Region Side k z MNI
Dorsolateral prefrontal cortex R 4527 4.48 42 28 40
Dorsolateral prefrontal cortex R 44 32 30
Dorsolateral prefrontal cortex R 44 18 30
Inferior frontal gyrus R 52 18 30
Dorsolateral prefrontal cortex R 40 8 62
Dorsolateral prefrontal cortex R 32 10 62
Dorsolateral prefrontal cortex L 1680 3.69 -48 22 40
Dorsolateral prefrontal cortex L -46 36 20
Dorsolateral prefrontal cortex L -44 8 34
Dorsolateral prefrontal cortex L -40 6 32
Dorsolateral prefrontal cortex L -32 10 60
Precentral gyrus L -38 4 26
Angular gyrus R 3041 7.22 50 -56 38
Angular gyrus R 48 -54 52
Lateral occipital cortex R 38 -68 54
Superior parietal cortex R 36 -54 52
Angular gyrus R 50 -56 44
Lateral occipital cortex R 32 -66 52
Occipital fusiform cortex L 10048 4.66 -40 -58 -24
Occipital fusiform cortex L -10 -80 -24
Occipital fusiform cortex L -16 -88 -24
Occipital fusiform cortex L -16 -80 -20
Occipital fusiform cortex R 16 -78 -14
Occipital fusiform cortex R 40 -66 -14
Lateral occipital cortex L 2865 4.21 -38 -62 50
Lateral occipital cortex L -46 -62 46
Angular gyrus L -46 -54 42
Superior parietal cortex L -48 -50 58
Angular gyrus L -40 -54 36
Angular gyrus L -42 -56 40
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Table A.4
Significant clusters of reward prediction error related activation during wins in
treatment resistant schizophrenia patients
Region Side k z MNI
Frontal pole R 630 3.67 6 74 14
Frontal pole R 38 62 -2
Frontal pole R 34 64 -4
Frontal pole R 20 74 8
Frontal pole R 4 74 8
Frontal pole R 28 58 -2
Inferior frontal gyrus L 1410 3.82 -54 14 30
Dorsolateral prefrontal cortex L -44 30 26
Inferior frontal gyrus L -50 12 24
Dorsolateral prefrontal cortex L -44 14 42
Dorsolateral prefrontal cortex L -48 10 38
Inferior frontal gyrus L -52 28 22
Dorsolateral prefrontal cortex R 1507 4.07 42 10 36
Dorsolateral prefrontal cortex R 48 8 36
Dorsolateral prefrontal cortex R 40 14 32
Inferior frontal gyrus R 48 10 22
Dorsolateral prefrontal cortex R 52 32 22
Dorsolateral prefrontal cortex R 30 4 54
Lateral occipital cortex R 1352 3.66 34 -64 42
Superior parietal cortex R 36 -44 46
Lateral occipital cortex R 22 -62 48
Lateral occipital cortex R 18 -66 48
Lateral occipital cortex R 36 -58 38
Angular gyrus R 52 -54 40
Occipital fusiform cortex R 7420 4.35 34 -78 -20
Occipital fusiform cortex R 10 -80 -16
Cerebellum L -34 -56 -26
Occipital fusiform cortex R 26 -84 -18
Occipital fusiform cortex L -24 -82 -18
Occipital fusiform cortex L -32 -74 -20
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Table A.5
Significant clusters of reward prediction error related activation during losses in
healthy controls
Region Side k z MNI
Middle frontal gyrus L 1291 3.92 -40 38 34
Middle frontal gyrus L -44 38 28
Middle frontal gyrus L -46 34 20
Middle frontal gyrus L -42 40 18
Middle frontal gyrus L -46 18 48
Middle frontal gyrus R 2627 3.87 42 34 36
Middle frontal gyrus R 54 30 36
Middle frontal gyrus R 50 26 36
Frontal pole R 28 60 26
Middle frontal gyrus R 30 16 50
Superior frontal gyrus L 1310 3.98 0 26 48
Superior frontal gyrus L -6 24 48
Paracingulate gyrus L -2 50 26
Superior frontal gyrus L -8 36 50
Superior frontal gyrus R 2 42 44
Putamen L 541 3.39 -24 -2 -8
Pallidum L -16 0 0
Thalamus L -8 -8 0
Putamen L -30 4 -8
Putamen L -34 0 -8
Thalamus R 558 1.44 28 -24 -4
Thalamus R 26 -28 0
Thalamus R 28 -24 0
Putamen R 30 -16 -6
Pallidum R 18 0 2
Superior parietal cortex R 2224 4.27 54 -42 46
Superior parietal cortex R 30 -64 50
Angular gyrus R 44 -52 48
Lateral occipital cortex R 34 -66 56
Angular gyrus R 46 -52 48
Superior parietal cortex L 1274 3.78 -50 -42 48
Superior parietal cortex L -46 -42 46
Superior parietal cortex L -38 -56 52
Angular gyrus L -44 -56 52
Supramarginal gyrus L -52 -46 48
Lateral occipital cortex R 1432 4.23 42 -90 6
Lateral occipital cortex R 28 -92 18
Lateral occipital cortex R 42 -66 -18
Lateral occipital cortex R 44 -82 -6
Lateral occipital cortex L 1217 3.94 -36 -90 -8
Lateral occipital cortex L -40 -70 -18
Occipital fusiform gyrus L -44 -64 -22
Lateral occipital cortex L -40 -84 -12
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Table A.6
Significant clusters of reward prediction error related activation during losses in
treatment resistant schizophrenia patients
Region Side k z MNI
Orbitofrontal cortex L 3028 8.11 -46 40 -6
Dorsolateral prefrontal cortex L -40 20 40
Inferior frontal gyrus L -50 20 26
Inferior frontal gyrus L -50 20 2
Frontal pole L -42 48 0
Frontal pole L -44 48 -10
Superior frontal gyrus L 5204 4.19 -2 38 42
Inferior frontal gyrus R 46 28 20
Frontal pole R 24 38 50
Dorsolateral prefrontal cortex R 40 22 24
Superior frontal gyrus R 6 32 42
Dorsolateral prefrontal cortex R 54 22 34
Lateral occipital cortex L 1426 3.83 -28 -62 56
Angular gyrus L -42 -56 56
Supramarginal gyrus L -50 -50 42
Angular gyrus L -52 -56 38
Lateral occipital cortex L -54 -64 28
Superior parietal cortex L -30 -54 58
Lateral occipital cortex R 12130 4.46 38 -76 -30
Occipital cortex R 16 -94 2
Cerebellum L -20 -82 -28
Occipital cortex L -26 -94 6
Occipital fusiform cortex R 34 -44 -22
Cerebellum L -24 -78 -30
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Table A.7
Means and standard deviations of demographic and clinical variables per group
HC NTR TRS
M SD M SD M SD Group statistics
F(2) P
Phonological verbal fluency 15.4 5.2 10.1 3.9 11.1 2.8 10.03 < .001
Semantic verbal fluency 19.7 4.4 14.3 4.0 14.5 3.4 12.96 < .001
Letter number sequencing 11.5 3.0 9.4 2.7 9.0 3.1 4.60 .014
ASI 7.3 7.4 10.8 9.0 18.9 5.9 11.07 < .001
BIS/BAS 60.4 11.5 64.5 8.7 70.8 12.6 5.36 .007
BIDR 125.1 17.3 126.5 13.3 120.2 18.1 0.28 .758
BDI 4.4 3.7 12.3 12.2 17.3 10.8 11.13 .001
HC = Healthy controls
NTR = non-treatment-resistant schizophrenia
TRS = Treatment resistant schizophrenia
ASI = Aberrant Salience Inventory
BIS/BAS = Behavioural inhibition / Behavioural approach system scale
BIDR = Balanced Inventory of Desirable Responding
BDI = Beck Depression Inventory
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